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DNA and interfering RNA (RNAi) – short interfering RNA (siRNA) and micro 
RNA (miRNA) – are promising new cancer therapies, especially for drug resistant lines.  
However, they require a delivery system in vivo to prevent degradation and off target 
effects.  Silica based nanoparticles, both solid and mesoporous, are a promising option due 
to their biocompatibility, ease of preparation and morphology control, reproducibility, and 
facile addition of functional groups including targeting ligands. 
 
After a brief introduction to cancer treatment and review of the current nanoparticle 
treatments undergoing clinical trials, this thesis details the many methods explored over 
the past ten years to fine-tune particle preparation, pore size, functionalization, and delivery 
strategies.  The majority of both solid and mesoporous silica nanoparticles are synthesized 
using the sol-gel method and then various functionalization techniques are employed to 
load and protect the oligonucleotides.  Externally loaded systems generally use a 
combination of polyethylenimine (PEI) and polyethylene glycol (PEG). Mesoporous silica 
nanoparticles internally load the DNA or RNAi, resulting in the added variable of pore 
size.  Several groups have investigated how pore size alters loading and release kinetics to 
perfect this variable.  Many groups have also tested ligands targeting for over expressed 
proteins on the intended cancer, triggered release techniques, cell-penetrating peptides in 
order to create a viable in vivo delivery system.  
 
By compiling the techniques employed by researchers over the past ten years, this 
thesis will elucidate which approaches are most promising for future research.  
Furthermore, overall strategies within the field are suggested to more easily compare 
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CHAPTER 1: INTRODUCTION TO SILICA BASED DELIVERY SYSTEMS 
FOR RNAI AND DNA IN CANCER TREATMENT 
1.1 The need for new cancer treatments 
Cancer is a costly disorder that results in much personal suffering even when 
treated. Improvements in early detection and treatment have increased cancer survival 
rates overall (Figure 1.1.) but not for some specific cancers.1 Death rates are rising for 
cancers of the oropharynx, anus, liver, pancreas, and soft tissue.2 For men there is an 
increase in tonsil cancer and melanoma deaths; for women there is an increase in uterine 
cancer deaths.2 Furthermore, cancer is now the second leading cause of death (23% of 
deaths in 2011 in the United States) after heart disease and is suspected to overtake heart 
disease as the leading cause of death within the next several years.2 
 
Figure 1.1. Cancer incidence and death rates from 1975 – 2011 adjusted to the 2000 US 




In addition to limited effectiveness in many cases, current treatments can result 
in debilitating side-effects and long-term effects depending on treatment and type of 
cancer. Common side-effects during chemotherapy and radiation treatment include 
anemia, digestive problems (constipation, appetite loss, etc.), cognitive problems, edema, 
fatigue, hair loss, infection, mouth ulcers, nausea and vomiting, among others.3 Long-
term effects vary based on therapy and type of cancer. For example, 25-60% of women 
develop chronic, though usually not severe, pain following breast cancer treatment.4 
Chemotherapy regiments containing oxaliplatin used to treat colon and rectum cancer 
often result in neuropathy.4 Consequently, new therapies are needed to improve cancer 
survival and better mitigate short and long-term side effects. One possible and promising 
solution to these problems is gene therapy. 
 
1.2 Brief history of gene therapy via nanoparticle delivery for treating cancer 
Gene therapy is a promising treatment for cancer that can treat cellular 
abnormalities by counteracting or correcting the malfunctioning gene within a cancerous 
cell.5 This treatment utilizes DNA or interfering RNA (RNAi) such as short interfering 
RNA (siRNA) or microRNA (miRNA). The delivered oligonucleotide either counteracts 
harmful protein production or corrects the aberrant gene. Both processes can result in 
cell death. However, delivery remains a significant obstacle. In the blood stream 
unmodified oligonucleotides are degraded by enzymes (RNases and DNases), are not 
taken up by target tissue, and can cause cellular immune response.6 Consequently, a 
delivery system is necessary for clinical translation of DNA and RNAi therapies. 
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The first therapy employing gene transfer was approved for clinical use in 2003 
by the Chinese State Food and Drug Administration. The gene delivery system 
Gendicine, a modified adenovirus, treats head and neck cancers by delivering the p53 
gene that, once expressed, promotes apoptosis of the targeted cell.7-8 However, a 
definitive report of phase IV safety and efficacy has not been published and Genedicine 
has not been approved by the US FDA.9 In fact, currently no gene therapies have gained 
FDA approval, although many organic and inorganic formulas are undergoing Phase I or 
II testing.10  
While gene therapy is promising, delivery of a therapeutic gene to cancer cells 
has proven to be the largest obstacle. Viral vectors, such as Gendicine, face several 
limitations such as safety concerns, effectiveness, and unintended immune response.11 A 
promising alternative is lipid, polymer, and silica nanoparticles that can have a diameter 
anywhere between 20-1,000 nm.12-14 These nanoparticle systems have higher loading and 
less safety concerns than viral vectors. Lipid nanoparticles form liposomes, phospholipid 
structures that assemble in water to form hydrophobic and hydrophilic compartments.15 
Neutrally charged liposomes are most often used, since negatively and positively charged 
liposomes can induce immune response in vivo.15 Polymer nanoparticles can be 
synthesized a number of ways (emulsion, interfacial polymerization, precipitation 
polymerization, etc.) and utilize different polymers depending on the intended cargo.16 
The final polymer nanoparticle can form a micelle or complex that traps the cargo in a 
matrix.17 One promising strategy uses polyethylene glycol (PEG) decorated block 
copolymers that self-assemble into polymer micelle nanoparticles and load hydrophobic 
cargo in the interior (such as CALAA-01, described in section 1.3).16 Silica nanoparticles 
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provide an easily tunable and modifiable platform to load cargo either on the exterior 
and/or within pores, depending on the morphology of the nanoparticle.18 
Nanoparticle formulas, both organic and inorganic, must overcome many 
challenges to be able to effectively deliver an oligonucleotide therapy. The majority are 
delivered systemically and, consequently, must contain peptides targeting overexpressed 
receptors on the specific cancer cell line to avoid damage to healthy cells. The 
nanoparticles must also encapsulate the gene to avoid its degradation and possible 
immune response.15, 19 They must avoid the reticuloendothelial system (RES), uptake by 
macrophages, long enough to find their target.20-21 Evading macrophage uptake can be 
achieved by reducing the particle’s diameter to below 250 nm and including exterior 
functionalization such as PEG.17 Larger particles are recognized by macrophages as 
foreign and are thus removed from the system and degraded.17  
In vivo efficacy is also determined by how the nanoparticle interacts with proteins 
and other components in blood, since studies have shown that the protein corona that 
occurs in serum can influence the nanoparticle’s uptake and behavior.22 The 
nanoparticle’s size, charge, and exterior functionalization with a ligand such a PEG alter 
the corona formed and, consequently, the fate of the delivery system.23 Most nanoparticle 
delivery systems are designed to penetrate the cell through the endocytosis pathway, 
either by specifically recognizing proteins on the nanoparticle’s exterior or independent 
of specific ligands.17 The endocytosis pathway results in the nanoparticle entering the 
cell in an endosome that is routed to a lysosome for degradation.24 The nanoparticle must 
escape the endosome to deliver its’ cargo in the cytosol, so the DNA or RNAi can 
successfully reach the nucleus or inhibit mRNA protein production.17 The particles 
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discussed in this thesis target endosomal uptake by limiting diameter to under 500 nm 
and including targeting functional groups. However, larger particles, such as 
microparticles, can be internalized via a phagocytosis route due to non-specific 
interactions between the particle and cell25-26 or via an actin-mediated process.27 Finally, 
nanoparticle systems must also be non-toxic and biodegradable.  
To date there are two dominant strategies for targeting delivery: passive and 
active. Passive targeting refers to systems that use the enhanced permeability and 
retention effect (EPR) to reach tumors. EPR occurs when a solid tumor grows large 
enough that normal vasculature is unable to provide enough oxygen and new blood 
vessels are built to support the cancer cells’ rapid growth.28 Once this happens, leaky 
vasculature develops in solid tumors, termed the EPR effect, that results in the 
accumulation of nanoparticles with a diameter less than 200 nm.29 However, 
formulations less than 50 nm in diameter usually are not retained in tumors for long, 
because they often undergo extravasation, leakage from the blood vessel to the tissue 
around it.29 Active targeting employs a ligand on the exterior of the particle that binds to 
a protein overexpressed on the intended cancer cell line. The promise of active targeting 
is to reduce off-target effects as much as possible by specific delivery. These two 
strategies are often used together. By utilizing both active and passive targeting, the 
nanoparticle reaches close enough proximity for the targeting ligand to bind to its 






1.3 Active targeting nanoparticles currently in clinical trials 
There are currently numerous organic and inorganic targeted nanoparticle 
treatments undergoing clinical trials for imaging and delivery of drugs, DNA, siRNA, 
cytokines, antigens, and monoclonal antibody delivery. These systems demonstrate the 
promise of precisely delivering a therapy while minimizing or eliminating harming 
healthy cells. Both organic and inorganic nanoparticles have an average diameter ranging 
from 5 – 200 nm and undergo both passive and active targeting. 
Most organic nanoparticles are liposomes with PEG conjugated to the exterior to 
increase circulation time and reduce clearance by immune cells.30-35 These nanoparticles 
encapsulate medications that would be degraded in the blood stream (such as DNA and 
RNAi) or cause serious side effects. For example, MM-302 loads doxorubicin30 that can 
cause severe chemotherapy-induced nausea and vomiting;36 SGT-53 loads genes, such 
as p53 cDNA37; and TKM-080301 encapsulates siRNA.38 Unlike the other nanoparticles 
delivering therapies directly to the tumor, Lipovaxin-MM is a liposomal 
immunotherapy/vaccine for malignant melanoma that targets dendritic cells to elicit an 
immune response against the targeted cancer cells.39 
Polymer nanoparticles are core-shell structure with the payload encapsulated.40-
41 CALAA-01 was the first targeted delivery system for siRNA tested in humans. It is a 
cyclodextrin-containing polymer with PEG for steric stabilization and a human 
transferrin protein-targeting agent.41 In clinical use it is prepared by mixing two 
components to produce the siRNA encapsulated polymer nanoparticle for intravenous 
injection.41 Another example is BIND-014 that uses hydrophobic polylactic acid 
polymeric core to encapsulate docetaxel.42 BIND-014 also uses a PEG coating in addition  
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to prostate-specific membrane antigen (PSMA) targeting ligands.42 Other preclinical 
studies include targeted core-crosslinked polymeric micelles where the drug, doxorubicin, 
is covalently trapped.50 
Whereas liposomes and polymer nanoparticles deliver a therapy directly to the 
tumor or, in the case of Lipovaxin-MM, to dendritic cells for immunotherapy, targeted 
inorganic nanoparticles are currently in clinical trials for biopsy and imaging. The 
superparamagnetic nanoparticles made of iron oxide (SPIONs) target CD34 surface 
receptors on leukemia cells in order to preferentially collect them during bone marrow 
sampling procedures.48 This technique has also been investigated in vivo for the detection 
of breast cancer by conjugating the single-core iron oxide nanoparticles to a Her2 
monoclonal antibody.51 Similarly, targeted PEGylated gold nanoparticles have 
undergone in vivo studies for imaging but are yet to begin clinical trials.52 
C dots, dye labeled core-shell silica nanoparticles, were developed for sentinel 
lymph node (SLN) mapping in the diagnosis and treatment of melanoma. For this 
application, the particle was modified with peptide ligands (cyclic arginine-glycine-
aspartic acid-tyrosine (cRGDY)) that is attached to methoxy-terminated PEG bound to 
the particle.49 Although C dots are currently only being investigated for SLN, they can 
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easily be modified with a different targeting ligand for an alternate tumor target. Thus, C 
dots and other silica based particles can be thought of as platforms. While C dots are the 
only silica based nanoparticle in clinical trials, silica based delivery systems are 
advantageous due to their biocompatibility, facile interior and exterior modification, high 
loading capacity, and ease of scaling up production.18 Silica nanoparticles can be 
synthesized to have mesoporous that can be optimized. Once this is achieved, internal 
and external modifications can be altered to produce controlled, targeted delivery to a 
variety of cancer cells. 
 
1.4 Advantageous of using silica nanoparticles for DNA and RNAi delivery 
Silica nanoparticles’ surface can easily be modified with alkoxysilanes and are 
biocompatible, making both solid and mesoporous silica based systems an attractive 
solution to deliver DNA and RNAi.53 Solid nanoparticles, like C Dots, can have polymers 
conjugated to their surface that load and protect nucleic acids.54 In addition to protecting 
the DNA or RNAi on the surface, a targeting ligand can be added for specific delivery.55 
For systems that internalize their cargo, mesoporous silica nanoparticles (MSN) 
are a promising platform due to their biocompatibility, high loading capacity, facile 
preparation and control of physical properties, large surface area, and ease of modifying 
both the pores and external surface. Particle size and pore size are tailored by altering 
synthesis conditions, both of which allow batch-to-batch reproducibility.54 The surface 
and pores can then be modified with different functional groups by using alkoxysilanes. 
The ease of altering the silica surface has resulted in triggerable drug release systems. 
This is usually achieved by covalently linking the drug to the nanoparticle with cleavable 
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bonds or functionalization of the outer surface of the MSN with a coating that will release 
the payload upon an environmental change, such as pH or temperature.56 Controlled 
release will likely be ready for clinical application in the near future, as numerous 
capping mechanisms are being explored in biomedical application for MSNs57 and have 
been shown to increase efficacy and efficiency.58 
Mesoporous silica nanoparticles (MSNs) have been shown to be biocompatible 
and excreted through urine and sometimes feces, depending on the particle’s size, surface 
area, and charge. Unlike other inorganic particles such as gold or iron oxide, silica 
nanoparticles can be biodegraded and excreted through the urine.59-60 In general MSNs 
are found to accumulate in the liver, spleen, and lungs, likely due to phagocytosis by 
macrophages.59 However, uptake by macrophages does not decrease their ability to 
function and ingest apoptotic or antibody-opsonized target cells.61 PEGylation reduces 
the biodistribution in these organs.59-60 Size also influences biodistribution. He and 
colleagues compared different particle sizes (80, 120, 200, and 360 nm) to investigate 
how size affected particle fate. They found the smaller particle sizes could avoid capture 
by the liver and spleen more easily and were consequently more slowly biodegraded.60 
Numerous studies have reported no pathological abnormalities of the mice injected with 
MSNs.60, 62-63 
The ease of pore modification allows efficient loading and controlled delivery to 
be achieved. In the case of siRNA and DNA, larger pores (8-23 nm) with positively 
charged modifications have been found to best load siRNA and DNA internally as 
opposed to smaller pores where the siRNA was unable to fully enter the pore.64-66 For 
example, 23 nm pores were found to adsorb more siRNA internally as compared to 2 nm 
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pores.64 While larger pores load more siRNA, release can be compromised. One study 
found that while multilayer adsorption could occur in 15 nm pores, 8 nm pores resulted 
in optimal loading and maximized release.67 The same study additionally found the 
degree of pore functionalization resulted in changes in loading capacity and subsequent 
release of siRNA for pores 8 nm or larger.67 Once pore size and functionalization is fine-
tuned, this system could be used for a variety of nucleic acids of similar size.   
  
1.5 General synthesis of solid and mesoporous silica nanoparticles 
Both mesoporous and solid silica nanoparticles are usually synthesized using the 
sol-gel method where a silica precursor hydrolyzes and then condenses to create spherical 
particles (Figure 1.2.). Tetraethyl orthosilicate (TEOS) is usually used as the silica 
precursor, since it allows a high degree of control based on varying synthesis conditions 
such as pH.68  
 
 










































An acid or base catalysis is usually used to increase hydrolysis and condensation 
of the silicon alkoxide. An acid catalyst reversibly pronates the negatively charged 
alkoxide ligand and forms a better leaving group for hydrolysis. Basic catalysts create 
better OH- groups for hydrolysis and deprotonated the silanol groups for faster 
condensation. Thus, hydrolysis is faster in acidic conditions, while condensation is faster 
in basic conditions.68 A surfactant is used to synthesize mesoporous silica nanoparticles. 
Surfactants have a long, hydrophobic tail and a hydrophilic head. The silica precursor 




Figure 1.3. A) The silica condensation reaction. B) The silica precursor electrostatically 
assembles around the cationic surfactant micelles. The silica then condenses around the 
surfactant, creating porous silica. The surfactant, CTAB, is represented as a squiggly line 
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1.6 Characterization techniques 
Several characterizing techniques are employed to determine instrumental 
features of solid and mesoporous silica nanoparticles. From nitrogen physisorption 
(porosimetry) a particle’s surface area, pore volume, and pore diameter can be 
determined. Diameter can be found either using transmission electron microscope 
(TEM), or the hydrodynamic diameter can be obtained using dynamic light scattering 
(DLS). External morphology is often ascertained using a scanning electron microscope 
(SEM). Finally, the particle’s charge can be estimated based on zeta potential that 
measures the charge at the boundary of strongly held charges and the bulk solution. 
 
1.6.1. Nitrogen physisorption (porosimetry) 
Nitrogen physisorption is used to characterize a porous material’s surface area, 
pore volume, and pore diameter. In this technique, the sample is first degassed in order 
to remove all physisorbed species.69 In isothermal conditions, nitrogen is then introduced 
at a slow enough rate that a quasi-equilibrium is reached between each increase in order 
to properly determine adsorption.70 Once adsorption is complete, desorption is measured. 
The graphed data, an isotherm, contains the amount adsorbed against the equilibrium 
relative pressure (P/Po), where Po is the saturation pressure of the adsorptive at the 
temperature of the measurement against P, the pressure when the temperature is above 





Figure 1.4. The left image is six characteristic isotherms. The right image is four common 
hysteresis loops. Image modified from reference 71. 
 
Most isotherms can be grouped into six categories, as seen in Figure 1.4. (left). 
For the purposes of the current project, isotherm IV is most applicable due to being 
characteristic of mesoporous materials.71 The initial section of the isotherm is due to 
monolayer adsorption where the nitrogen gas is adsorbed onto the silica surface.69 The 
end of monolayer adsorption and beginning of multilayer adsorption is indicated by the 
arrow on Type II and IV. The change in slope is due to the shift from adsorbent-
adsorptive interactions to interactions between the gas molecules in their condensed 
state.72 The gas molecules in multilayer filling interact with the already adsorbed nitrogen 
gas and are thus assumed to have liquid-like properties.70 The hysteresis loop, or the loop 
between the adsorption and desorption, is a result of the capillary condensation occurring 
in mesopores.69 This occurs at a high P/Po for mesoporous materials, since capillary 
condensation is secondary to multilayer adsorption.70 The desorption branch is a result 
of delayed condensation due to the metastability of the adsorbed multilayer.72 
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Hysteresis loop can be further characterized, as seen in Figure 1.4. (right). The 
differences between these four examples have been correlated with various pore 
structures. 69 Type H1 is often associated with approximately uniform pores in a fairly 
regular array with narrow pore distribution; H2 is not well defined but is usually due to 
porous adsorbents (e.g. porous glass); H3 is attributed to plate-like particles with slit-
shaped pores; H4 is associated with narrow slit-like pores or microporosity. 69 
Porosimetry also allows the surface area to be derived using the Brunauer-
Emmett-Teller (BET) gas adsorption method. This method relies upon the amount of gas 
adsorbed at the relative pressure P/Po and the monolayer capacity.69 Pore volume and 
diameter are derived using the Barrett-Joyner-Halenda (BJH) method. 
 
1.6.2. Dynamic light scattering (DLS) 
DLS uses a laser (usually 675 nm) and photodetector to determine a small 
particle’s geometric structure by measuring its Brownian motion or the random 
movement of microscopic particles in a fluid due to the bombardment from other 
molecules in the medium.73-74 The photodetector is 90° from the laser in order to capture 
light scattered by the suspended particles. The particles size and shape can be determined 
based on the frequency shifts, angular distribution, polarization, and intensity of the 
scattered light.74 
 
1.6.3. Zeta potential 
Zeta potential is the potential difference between the slipping plane, where the 
nanoparticle and ions act as a single entity and move together under an applied electric 
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field, and the bulk solution.75 The charge difference is determined by measuring the 
frequency shift of scattered light of a nanoparticle moving under an applied field, which 
indicates its electrophoretic mobility and can be used to calculate its zeta potential.75 Zeta 
potential indicates the surface charge but is not a direct measurement. Since it also uses 
light scattering, zeta potential is measured in the same instrument as DLS. 
 
1.6.4. Scanning and transmission electron microscopy 
In scanning electron microscopy (SEM) an electron probe between 0.5-10 nm in 
diameter scans over the specimen.76 An image is then produced by different signals from 
secondary electrons (exit energies around 2-5 eV) and backscattered electron (around 50 
eV) that alter the cathode-ray tube’s beam intensity.76 The cathode-ray tube produces the 
image based on the altered signal due to electron-specimen interactions.76 
Transmission electron microscopy (TEM) differs from SEM in that the electron 
beam penetrates a thin specimen. TEM has higher accelerating voltages and a broad, 
static beam.77 The electrons pass through a thin specimen and interact strongly via elastic 
and inelastic scattering.77 The scattered electrons are collected and focused to project an 
image. 
 
1.7 Thesis goals 
Since silica based delivery systems are uniquely poised solve the obstacles facing 
DNA and RNAi delivery, this thesis will investigate the strategies published in the last 
ten years to develop a silica based gene delivery system. Two main strategies, solid silica 
nanoparticles and mesoporous silica nanoparticles, will be discussed. While strategies 
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will be compared in some cases, the variation between each study (preparation method, 
particle functionalization, evaluation techniques) presents significant difficulty in 
appropriately contrasting specific technical components.78 Thus the goal of this thesis is 
to both highlight the areas where creating a benchmark would further the field of 
research78 and identify the most promising techniques being pursued toward developing 
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CHAPTER 2: EXTERNAL CONJUGATION DELIVERY SYSTEMS 
 
2.1 Preparation methods 
There are two main silica systems using conjugation of DNA or RNAi to the 
exterior of the silica for gene therapy: solid and mesoporous with very small pores. Most 
of the systems are synthesized using the sol-gel method where a colloidal solution or sol 
is created and then assembled upon through condensation. The mesoporous system uses 
surfactant that produces pores through self-assembly by the silica precursor around the 
surfactant. However, in some cases the pores are too small after surface functionalization 
to allow for loading DNA and RNAi in the pores, so external conjugation is used.  
Variations in preparation method alter the particle size and morphology as well 
as determining how easily production could be scaled up for clinical use. The silica core’s 
size and morphology alters the outcome of the particle in vivo.1 Thus, a primary goal is 
to produce a base particle that is biocompatible and successfully delivers its’ therapy in 
vivo upon which targeting and oligonucleotide specific functionalization can be altered 
based on the cargo and target. 
 
2.1.1. Solid silica systems 
Several preparation methods have been used to synthesize the solid silica core for 
DNA and RNAi delivery. The most common strategy is the sol-gel method that involves 
hydrolysis and then condensation. Xiao and colleagues2 and Buchman and colleagues3 
both prepared their solid silica particles via this method. Their method involved using 
ammonium as the base catalyst, absolute ethanol, and TEOS. Buchman’s group produced 
24 
 
nanoparticles with an average diameter of 31.5 ± 5.2 nm based on TEM measurements 
and a zeta potential of -26.5 mV determined by a Zetasizer Nano.3 Xiao and colleagues 
added thionyl chloride and benzene in order to produce chlorinated silica for their 
functionalization. This mixture was stirred for 50 hours.  Both zeta potential and size 
were measured after the chlorinated SNPs were functionalized with amino groups. The 
final product was nearly spherical in shape, had a diameter of 20-30 nm based on DLS, 
and a zeta potential of +11.3 mV.2 
Ye et al. modified the sol-gel method to produce cross-linked hybrid organosilica 
NPs from gelatin/3-glycidoxypropyl-trimethoxysilane (GPSM) and (3-
aminopropyl)trimethoxysilane (APTMS) (Figure 2.1.). This method was developed to 
simplify preparation and avoid environmentally harmful solvents.4 In acidic conditions 
GPSM’s epoxy group was protonated and thus activated to undergo a nucleophilic attack 
from the NH2 side chain on gelatin.5 The sol was formed by the GPSM/gelatin molecule, 
since the methoxy silane groups (Si-OCH3) of GPSM was hydrolyzed to produce Si-
OH.5 The hydrophilic portion where gelatin attached to GPSM forms the inner section 
on the sol.4 Once APTMS is added, the pH is changed to 8-9. This basic solution caused 
the hydrolyzed GPSM and APTMS molecules to co-condense and form a siloxane 
network.5 The amine group from APTMS is mainly on the exterior of the nanoparticles, 
because the GSNPs form organized micelles where the hydrophilic portion is on the 
interior and the hydrophobic portion containing the amine is on the exterior.4 This was 
confirmed by silicon-29 cross-polarization magic angle spinning nuclear magnetic 
resonance spectrum (29SiCP/MAS NMR) that found condensation of Si-OH groups were 





Figure 2.1. Synthesis of GSNPs. Image adapted from reference 4. 
 
Another method was used by Rejeeth and colleagues by forming non-polar cores 
in a micellar medium made from the surfactant (Aerosol OT (AOT)), co-surfactant (n-
butanol (BuOH)), and water.6 Dimethyl sulfoxide (DMSO) creates the nonpolar core 
around which AOT, BuOH and water micelles form. Vinyltriethoxysilane (VTES) and 
3-aminopropyltriethoxysilane (APTES) are hydrolyzed together to form a hybrid amino-
functionalized nanoparticle.6 The resulting silica nanoparticles were separated from AOT 
and BuOH by dialysis and re-suspended in water.6-7 The final nanoparticle had a mean 
diameter of 54 nm (determined with transmission electron microscopy (TEM)) and a zeta 
potential of approximately 8 mV due to the positively charged amine groups in APTES. 
The benefit of this synthesis method include avoiding additional purification steps due 
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to grafting amines post particle formation and the addition of organic groups is thought 
to add some degree of flexibility to the rigid silica matrix.6  
 
2.1.2. Mesoporous systems for exterior loading 
The sol-gel method is also the most common strategy to synthesize mesoporous 
silica nanoparticles for external loading. Ngamcherdtrakul and colleagues prepared 47-
nm mesoporous silica core with the base catalyzed sol-gel method using 
cetyltrimethylammonium chloride (CTAC) as the surfactant to form the pores, 
triethylamine (TEA), and TEOS as the silica precursor.8 TEA, a base, and CTAC are first 
mixed in water before TEOS is added. The particles are formed first by TEOS being 
hydrolyzed. The silica precursor then condenses and forms the seeds from which the 
particles are built.9 TEA, a base, acts to keep these seeds apart during the condensation 
process by retarding hydrolysis of TEOS’ alkoxides.10 The CTAC’s ammonium anions 
act as a structure directing agent due to their positively charged NH4+ head around which 
the silica precursor self-assembles during the co-condensation process by forming the 
pores.10 The surfactant was removed by being refluxed in methanol and hydrochloric acid 
overnight.8 The silica nanoparticle’s diameter used in the study was 47-nm based on TEM 
measurements.8  
 
2.2 External functionalization 
Delivery systems where the oligonucleotide is loaded on the nanoparticle’s 
exterior use cationic functional groups to electrostatically attach and protect the 
negatively charged DNA or siRNA. External functionalization, such as PEG, also acts to 
27 
 
protect the gene or RNAi from degradation by enzymes like DNase 1 by repelling 
proteins in the bloodstream.6 External cationic functionalization has the added benefit of 
binding with high affinity to the lipid groups of a cell due to their negative charge 
resulting in endocytosis,11 although positively charged nanoparticles are taken up by the 
immune system in vivo.12 Thus, PEG is often used to reduce immune system uptake. 
Decorating the exterior with a polymer such as polyethylenimine (PEI) results in 
endosomal swelling and eventual rupture leading to endosome escape, which is necessary 
for successful transfection.12 PEI accomplishes endosomal escape, because its’ 
unsaturated amino groups bind with free protons in the endosome.11 This causes the 
proton pumps (v-ATPase) to continue pumping protons into the endosome to replenish 
the protons bound to the PEI. For each proton pumped into the endosome, one free 
chloride and water to enter the vesicle.11 The extra water molecules cause swelling and 
the eventual rupture that allows the nanoparticle to escape to the cytoplasm.11   
 
2.2.1. Amino groups for gene and siRNA loading 
Several groups used an amino group exterior to load and protect siRNA. For 
example, Rejeeth and colleagues loaded p53 onto their particles by first functionalizing 
the exterior with a synchronous hydrolysis of vinyltriethoxysilane (VTES) and 3-
aminopropyltriethoxysilane (APTES).6 DNA electrostatically attached to the positively 
charged amino groups on the particle’s surface. Once loaded, the particle diameter 
increased to an average of 59 nm to 113 nm based on TEM measurements.6 Zeta potential 
on the loaded particles was reported to be more positive than preloaded NPs, 8 mV and 
13 mV respectively based on analysis by electrophoretic light scattering 
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spectrophotomer.6 This result is counter to the other studies in this review where loading 
negatively charged plasmid DNA (pDNA) reduces a system’s zeta potential. 
Unfortunately, the authors do not address this abnormal reading. 
Successful loading and delivery of the pDNA was demonstrated with an in vitro 
growth assay using MCF-7 cells (Figure 2.2.). The cells were transfected with either the 
unloaded nanoparticles (control), p53 alone, p53 loaded onto their nanoparticles 
(ORMOSILNs), or p53 loaded in Lipofectin®. After transfection, the number of viable 
cells was determined. Cell growth was significantly inhibited by the p53/ORMOSILNs 
treated group compared to the control and free p53 treated groups. Their system also out 
performed p53 loaded Lipofectin. 
 
 
Figure 2.2. In vitro growth inhibition of MCF-7 cells after transfection with unloaded 
nanoparticles (control), free p53, ORMOSILNs loaded with p53, and Lipofectin loaded 
with p53. *p < 0.05 compared with the in vitro growth inhibition of the control. Image 




Like Rejeeth’s group, Xiao and colleagues used amino groups to electrostatically 
attach the p53 gene.2 They functionalized their NPs’ surface by first chlorinating the 
silica by including thionyl chloride with benzene in their particle preparation (Figure 
2.3.). This produces a surface of Si-Cl bonds that will react with an alcohol or amine to 
form Si-O or Si-N linkages.13 The advantage of this method is that it eliminates 
competition between intermolecular reactions and surface attachment.13 In order to 
ensure alcohol attachment to the surface and external amino functionalization, Xiao and 
colleagues used 3-(Fmoc-amino)-1-propanol. The Fmoc group was then removed in 
piperidine in DMF. The average diameter of the modified particles (AMSNs) was 20-30 
nm as determined by DLS and the zeta potential was 11.3 mV.2 
 
 





































DNA was electrostatically attached to the amino modified nanoparticles by 
incubation. To determine whether the DNA bound to the functionalized particles, the 
group used agarose gel electrophoresis (Figure 2.4.). Once DNA was bound to the 
nanoparticles, the entire complex would weigh too much to travel on the gel. The 
mobility of DNA was retarded after a weight ratio of 30 nanoparticles to 1 DNA.2 The 
high ratio of nanoparticles to DNA implies the positive charge of multiple nanoparticles 
is necessary to electrostatically bind the negatively charged DNA. This suggests the 
external modification employed would not be adequate for in vivo delivery. 
 
 
Figure 2.4. Examining the binding capacity of AMSNs with agarose gel electrophoresis. 
DNA mobility was retarded once complexed with the AMSNs. Lane 1: control plasmid 
DNA. Lane 2-7 NPs to DNA ratios (w/w) of 1:1, 5:1, 30:1, 50:1, 100:1. Image modified 
from reference 2. 
 
Transfection efficiency was found to be approximately 48% when measured by 
fluorescence microscopy (Figure 2.5.). Xiao’s group used the reporter plasmid p53 
enhanced green fluorescent protein (pp53-EGFP) to measure transfection in HepG2 cells. 
When comparing transfection efficiency between their system (60 µg) and Lipofectin (8 





Figure 2.5. Fluorescence microscopy analysis of pp53-EGFP transfected HepG2 cells. A) 
Amino functionalized nanoparticles B) Lipofectin. Image modified from reference 2. 
 
 
Figure 2.6. Western blot analysis of p53 protein expression in pp53-EGFP transfected 
cells. Free DNA (pp53-EGFP) resulted in very little protein expression, while AMSN and 
Lipofectin loaded nanoparticles resulted in similar expression. a-tubulin was consistent 
across treated groups. Image modified from reference 2. 
 
Ye and colleagues also tested external amino groups to externally load 
oligonucleotides. They conjugated the amino groups to solid gelatin-silica nanohybrids 
(GSNPs) as well as three fusion peptides: Tat, R8, HA2.4 The Tat peptide, originally 
discovered on HIV-1, has been found to cause cell uptake of a wide variety of 
molecules.14 The N-terminal domain of influenza virus hemagglutinin-2 (HA2) may 
cause membrane lysis at low pH thus mediating endosomal escape.4 Octaarginine (R8) 
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has been shown to enhance cellular uptake and endosomal escape of liposomes.15 In all 
they tested six different surface chemistries: plain GSNPs (GS), Tat (GS-Tat), HA2 (GS-
HA2), R8 (GS-R8), Tat/HA2 (GS-TH), and Tat/R8 (GS-TR) modified GSNPs. To 
conjugate the fusion peptides to the particles’ surfaces, thiol groups were introduced 
using succinimidyl 3-(2-pyridyldithio)propionate (SPDP) reagent (Figure 2.7.). This 
allowed sulfhydrl-containing peptides to easily be conjugated to the nanoparticle’s 
surface using disulfide bonds. The ratio of peptides to gelatin-silica for all six groups was 
approximately 1.58 µmol/mg.4 DNA loading was then performed by incubating the DNA 
with the final particles at 100 µg/mL.4 The final particles with complexed DNA had a 
mean diameter of 190-230 nm determined with DLS and a positive zeta potential of +20-
22 mV based on Zetasizer Nano measurements.4 
 
 
Figure 2.7. A) Conjugation of the three sulfhydryl-containing peptides to GSNPs. B) 























































In vitro studies and intratumor injection in vivo both demonstrated that the GSNP-
Tat/HA2 (or GSNP-TH) nanoparticles transfected the most genetic material (Figure 
2.8.).4 However, intravenous injection of the plain GSNP and three fusion peptide 
decorated GSNPs resulted in the majority of luciferase gene expression in the liver and 
spleen with low levels of gene expression in the tumor.4 This is likely due to immune 
system uptake into the reticuloendothelial system (RES). In future research the group 
will likely explore using PEG in addition to the cell penetrating peptides in order to 
escape the RES and improve circulation time.4 Extended circulation time will improve 
the likelihood of the nanoparticle system arriving close enough to its’ intended target for 
the uptake moiety to work. The in vivo group also did not demonstrate significant 
differences between peptides. Further studies are needed to determine whether the in 
vitro findings translate to intravenous administration. 
 
 
Figure 2.8. The above graphs used luciferase quantification via an FB12 luminometer. A) 
In vitro transfection of the luciferase gene (pGL3) into HeLa or HEK-293 cells with the 
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six different external modifications. B) In vivo expression of the luciferase gene in the 
liver, spleen, lung, kidney and tumor via intratumoral injection. C) In vivo expression of 
the luciferase gene in the liver, spleen, lung, kidney, and tumor via intravenous injection. 
Image modified from reference 4. 
 
2.2.2. Polymers for DNA and siRNA loading 
Polymers are often used to functionalize the exterior of nanoparticles due to their 
ability to compact and deliver RNAi and DNA. PEI and PEG are most commonly used. 
PEI aids in transfection by increasing the influx of hydrated protons due to its 
unprotonated secondary and tertiary amines.8 PEG prevents corona formation, improve 
circulation times, protect siRNA from enzymatic degradation by providing steric 
protection.16 Shorter chain PEI (<10 kDa) have been shown to not lead to significant 
toxicity in a range of normal and tumor cells.17-18 
Buchman and colleagues created an siRNA delivery platform using base prepared 
solid silica nanoparticles (32.8 nm based on TEM images) with APTES covalently 
attached to the particle’s surface and PEI 25 kDa attached to the amine by a bis-Michäel 
acceptor divinyl sulfone (DVS) linker (Figure 2.9.).3 The aim of using DVS to attach the 
25 kDa PEI is to mitigate the branched polymer’s toxicity. The process of 
functionalization requires first functionalizing the exterior with APTES to distribute free 
amines on the surface. DVS was then added in a 1:1 ratio with respect to APTES.3 After 
two hours of stirring, the particles were washed and various amounts of  25 kDa PEI were 
added. The final system had an average TEM diameter of 34.2 ± 4.2 and a zeta potential 





Figure 2.9. The exterior functionalization of Buchman et al.’s delivery system. The silica 
base is first functionalized with APTES, resulting in the amine exterior on the nanoparticle 
on the left. DVS is then added with i-PrOH and the mixture is stirred for two hours. Finally, 
25 kDa PEI is attached by stirring at room temperature overnight. Image modified from 
reference 3. 
 
The final particles successfully complexed with siRNA with the most effective 
PEI/siRNA w/w ratio being 2:1.3 This was determined by using two luciferase proteins, 
Firefly and Renilla, to investigate in vitro gene silencing and toxicity (Figure 2.10.). 
Both Firefly (61 kDa) and Renilla (36 kDa) luciferases are oxidative enzymes that 
produce bioluminescence upon oxidizing their specific substrate.3 Since both reporters 
use different substrates and produce bioluminescence at different wavelengths, the dual 
luciferase system allowed measurement of the specific silencing of Firefly luciferase due 
to delivered siRNA and Renilla luciferase due to nanoparticle induced toxicity.3 A 
constant amount of siRNA targeting Firefly luciferase (100 nM) was used and the weight 
of 25 kDa PEI was varied in order to determine the optimal weight ratio for in vitro 
delivery while avoiding toxicity.3 The group compared this data to free 25 kDa 
complexed with Firefly luciferase targeting siRNA to establish whether the nanoparticle 
improved efficacy. The nanoparticle system demonstrated a high level of Firefly 
luciferase silencing (69%) while demonstrating cellular viability.3 Higher PEI/siRNA 
ratios (2:1 and 5:1) demonstrated increased silencing effects (90% and 89% respectively) 
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without any observed toxicity.3 Greater weight ratios resulted in the reduction of Renilla 
luciferase’s signal, indicating toxicity. The need for a greater PEI/siRNA ratio than 1:1 
is likely due to the resulting charge of the polyplex.3 The 1:1 ratio resulted in a zeta 
potential of -30.1 mV that likely decreased cell uptake and endosomal escape, while 2:1 
PEI/siRNA had a zeta potential of 10.4 mV.3 The 2:1 nanoparticles did display a 
tendency to aggregate that could be alleviated by either conjugating PEG to the PEI or 
increasing the zeta potential by using a weight ratio of 5:1 PEI/siRNA (26.3 mV). 
 
 
Figure 2.10. Luciferase levels 48 hours after transfection. A reduction in Firefly 
demonstrates successful gene silencing, while a reduction in Renilla demonstrates toxicity. 
A) siRNA complexed on NP and B) free 25 kDa PEI/siRNA. Image modified from 
reference 3. 
 
The free PEI/siRNA complex also silenced Firefly luciferase but with greater 
toxicity at higher weight ratios. At a 10:1 PEI/siRNA ratio, the nanoparticle complex 
reduced Renilla luciferase expression much less (94%) than the free PEI/siRNA complex 




Other groups synthesized a larger polymer shell that would further protect the 
transfection agent and, due to its increased charge, load more nucleic acids. Lee et al. 
sought to achieve greater cell transfection and siRNA loading by using PEI, PEG, and 
trimethoxy(3-(oxiran-2-ylmethoxy)propyl)silane (3-GTMS).19 Their three-step method 
involves synthesizing the block-copolymer from PEI (25 kDa) and PEG (5 kDa), 
modifying the block-copolymer with 3-GTMS to include a silane, and then conjugating 
the product of the second step to the silica nanoparticles (Figure 2.11.). The final system 
had a high zeta potential of 66 mV based on Zetasizer Nano analysis.19 The high zeta 
potential is likely due to the thick copolymer shell (12-15 nm based on TEM) on the 28-
30 nm core nanoparticle.19 The group used a gel retardation assay to determine which 
weight percent resulted in the most protection for siRNA. Ratios of 1:5 to 1:15 (siRNA 
undefined wt%:particles wt%) were the most stable, although the optimal weight percent 
was found to be 1:10 to protect the siRNA from RNAse as well as allow for cellular 
delivery.19 The system demonstrated low cytotoxicity in vitro when transfected in human 
alveolar basal epithelial cells (A549) and is being explored as a platform to develop a 
hybrid nanoparticle for MR imaging and siRNA transfection.19  
Ngamcherdtrakul et al. similarly used PEI and PEG to load siRNA and attach a 
targeting ligand to their base prepared, mesoporous silica nanoparticle (47 nm diameter). 
In their method, PEI was first coated on the exterior of the MSNP. Once complete, the 
PEI-MSNP was crosslinked using dithiobis(succinimidyl propionate) (DSP), an amine-
reactive crosslinker with an N-hydroxysuccimidine (NHS) ester at each end and a 
disulfide bond in the spacer arm. This disulfide bond is cleaved by reduced glutathione 




Figure 2.11. The three-step prep for the external polymer layer for siRNA loading and 
delivery. Image modified from reference 19. 
 
outside the cell.20 Thus, the siRNA cargo loaded within the PEI is released upon entering 
the cell. PEG was then conjugated to the primary amine of MSNP-PEI by using 
maleimide-PEG5kDa-NHS.8 Finally, the HER2 antibody trastuzumab was conjugated 
with the thiol-maleimide reaction by thiolating the antibody with 2-iminothiolane 
(C4H7NS) and then mixing it with MSN-PEI-PEG.8 The optimal formulation had an 
average hydrodynamic diameter of 117 nm determined by DLS and an average zeta 
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Compared to Lee and colleague’s surface modification method using a higher 
weight PEI, Ngamcherdtrakul’s group found 10-kDa PEI to provide optimal gene 
silencing efficacy (76%) while minimizing the use of PEI due to toxicity concerns.8 This 
is consistent with other studies’ results where reducing the chain length of PEI increases 
the MSNs’ safety profile.18 The group measured silencing efficacy by delivering siRNA 
targeting HER2 to HER2+ breast cancer cell lines. 
The targeting moiety’s ability to target HER2+ expressing cancer cells was 
demonstrated in vitro by measuring cell uptake in two HER2+ breast cancer cells, BT474 
and SKBR3, and one HER2- cell line, MCF-7 (Figure 2.12.). Scrambled siRNA was 
tagged with Alexa 488, a fluorophore to quantify uptake (siSCR). The two trastuzumab 
groups targeting HER2+ cell lines were T-siSCR-NP1.8C with 1.8 kDa PEI and T-siSCR-
NP10C with 10 kDa PEI. The negative control was two different PEI-conjugated 
nanoparticles conjugated with rituximab targeting CD20 (R-siSCR-NP1.8C with 1.8 kDa 
PEI and R-siSCR-NP10C with 10 kDa PEI). The two different weights of PEI were used 
in order to test whether the efficacy of the siRNA loaded nanoparticles could be increased 
by increasing the particle’s buffer capacity.8 Polymers like PEI have buffering capacity 
in the pH range of 5-7 due to their unprotonated secondary and tertiary amines, which is 
believed to result in the proton sponge effect and, consequently, endosome escape.8 For 
example, an estimated 15% of nitrogens are protonated on PEI in the extracellular space 





Figure 2.12. Cellular uptake of siRNA carrying nanoparticles bearing trastuzumab or 
rituximab targeting moieties. R-siSCR-NP1.8C is functionalized with 1.8-kDa PEI and R-
siSCR-NP10C with 10-kDa PEI. A) BT474 (HER2+) taken at two time points, 0.5 and 2 
hours B) SKBR3 (HER2+) taken at 2 hours C) MCF7 (HER2-) taken at 2 hours. Image 
modified from reference 8. 
 
The two systems also differed in the amount of PEG: R-siSCR-NP1.8C had 6.1% 
PEG and R-siSCR-NP10C had 18.2% PEG based on TGA measurements.8 This is likely 
due to the higher molecular weight of PEI between the two groups, since the 10 kDa PEI 
contains more reactive amine groups for PEG binding than 1.8 kDa PEI.8 The amount of 
Alexa-488 tagged siRNA in the interior of each cell was measured using flow cytometry. 
In the two HER2+ cell lines (Figure 2.12.) the trastuzumab and 10 kDa PEI 
functionalized delivery system outperformed the 1.8 kDa PEI decorated system. The 
trastuzumab targeting system also successfully targeted HER2+ cell lines and did not 
transfect HER2- cell line. 
In order to confirm successful siRNA delivery and HER2 suppression, 
Ngamcherdtrakul and colleagues delivered HER2 targeted siRNA to three HER2+ breast 
cancer lines: BT474, SKBR3, and HCC1954 (Figure 2.13.). They used quantitative 
immunofluorescent imaging to determine HER2 protein levels for T-siHER2-NP10C and 
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T-siSCR-NP10C. The nanoparticle system delivery HER2 targeting siRNA reduced HER2 
levels by 81%-93% compared to the scrambled siRNA system.8 This confirms successful 
siRNA delivery and targeted protein suppression. 
 
 
Figure 2.13. HER2 expression in three HER2+ breast cancer cell lines 72 hours post 
incubation with siHER2 or siSCR delivered via trastuzumab decorated nanoparticles. 
Image modified from reference 8. 
 
When evaluated in vivo via intravenous tail injection of T-siHER2-NP10C to treat 
the breast cancer xenograft HCC1954 (a tissue graft from a human donor), 
Ngamcherdtrakul’s group found 58.6% tumor reduction compared with saline control (p 
< 0.0013) and 46.5% (p < 0.015) compared to the control T-siSCR-NP10C, nanoparticles 
carrying a scrambled siRNA coupled with trastuzumab.8 The tumor reduction caused by 
the control T-siSCR-NP10C is likely caused by the targeting moiety trastuzumab, since it 
is known to cause HER2 reduction.8 While the study demonstrates effectiveness in 
treating resistant tumor lines, the study did not include information concerning the in 






2.3 Chapter Conclusion 
Several methods have been pursued to synthesize silica nanoparticles for loading 
DNA and RNAi on the particle’s exterior. The most commonly used method is the sol-
gel method. Two groups, Rejeeth et. al and Ye et. al, modified the sol-gel procedure to 
incorporate amines during synthesis to reduce procedural and purification steps. The sol-
gel synthesized solid nanoparticles had a diameter of 20-31.5 nm, whereas Rejeeth et. 
al’s procedure produced 54 nm particles and Ye et. al’s method resulted in 140-160 nm 
particles. Thus, a range of solid silica nanoparticles with different diameters have been 
produced and could be compared for in vivo and in vitro efficacy.  
Ngamcherdtrakul et. al created mesoporous silica nanoparticles functionalized 
with PEI and PEG to externally attach siRNA. The mesoporous silica nanoparticles could 
be used for dual delivery of an internally loaded drug and externally attached RNAi, since 
drug molecules are smaller than siRNA.8 This may be a promising strategy for externally 
loaded systems to treat cancer, since siRNA combined with medications like doxorubicin 
have been shown to overcome drug resistance in cancer cells.22 
Both amino groups and polymers have been investigated for loading DNA and 
RNAi for delivery to cancer cells. While some studies demonstrated cell growth 
inhibition due to oligonucleotide loaded amine decorated nanoparticles, the particle 
systems may be aggregating to load DNA as in Xiao et. al’s study.2 They found a ratio 
of 30 nanoparticles to 1 DNA necessary for complexation but a transfection efficacy of 
48% in vitro.2 These aggregations would likely not remain viable during in vivo 
application and increase the delivery system’s diameter. Future studies should investigate 
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the necessary ratio required to complex the desired oligonucleotide in addition to in vitro 
efficacy to produce a viable system for clinic. 
Polymer decorated nanoparticles exhibited relatively high transfection and 
protein suppression rates in a number of different cell lines. Most promising is the 
combined use of PEI for endosomal escape and PEG to protect the loaded 
oligonucleotides by repelling blood proteins. While more studies are needed in order to 
determine the optimal PEI weight, Ngamcherdtrakul et. al demonstrated 10 kDa PEI as 
more effective than 1.8 kDa PEI while not increasing toxicity.8  
In addition to improving delivery, targeting ligands can easily be conjugated to a 
polymer exterior. Ngamcherdtrakul et. al showed significant targeting specificity for 
cancerous cell lines using the targeting antibody trastuzumab.8 Hopefully future studies 
will indicate the overall in vivo fate of the particles to confirm the targeting effectiveness 
of the system.  
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CHAPTER 3: PORE LOADING DELIVERY SYSTEMS 
 
3.1 Optimizing pore size and functionalization for encapsulating oligonucleotides 
The first hurdle in encapsulating oligonucleotides for delivery by mesoporous 
silica nanoparticles is synthesizing a particle with optimal size pores for loading and 
release. Mesoporous silica is generally produced using the sol-gel method where a silica 
precursor and surfactant self-assemble to form pores. The pores can then easily be 
expanded by swelling the surfactant with 1,3,5-trimethylbenzene (TMB) or etching the 
silica with ammonium hydroxide. TMB can penetrate the micelles forming the pores 
(Figure 3.1.) due to the hydrophobic forces between the surfactant alkyl chain and 
TMB.1 This caused the micelles to expand, widening the pores. Surfactant is then 
removed either through solvent extraction or high temperature calcination (>500 °C) that 
evaporates the surfactant and condenses the silica. 
 
 
Figure 3.1. Surfactant structure with the swelling agent TMB in its center. TMB causes 
the micelle to increase in size. However, swelling agents can cause disorder and 




3.1.1. Loading pDNA and DNA 
Kim and colleagues synthesized MSNPs with two different pore sizes, 2 nm and 
23 nm, in order to evaluate the dependence of pore diameter on gene uptake and 
delivery.3 The particles were synthesized at a basic pH using CTAB and tetramethyl 
orthosilicate (TMOS). This produced MSNPs with 2.1 nm pores (MMSN-2). The 23 nm 
pore nanoparticles (MMSN-23) were prepared by soaking the as-synthesized 
nanoparticles in ethanol, water, and TMB at 140 °C for four days. After removing the 
surfactant by refluxing in an acidic ethanolic solution, the nanoparticles were 
functionalized with amine groups via APTES (3.6 mmol/g) (Figure 3.2.). The group 
reported both particles had a diameter of approximately 250 nm based on TEM images 
and the degree of amination was determined to be 3.6 mmol/g by elemental analysis.3 
 
 
Figure 3.2. Amine functionalization of the pore interior and the MSN exterior using (3-
amnopropyl)triethoxysilane (APTES). 
 
Kim and colleagues reported the MMSN-23 could adsorb more plasmid DNA 
(pDNA) internally than MMSN-2 based on zeta potential readings and gel retardation 
assay results (Figure 3.3.). The group used a pDNA encoding for luciferase (pLuc, 4.8 
kbp).3 Zeta potential measurements remain positive before and after pLuc loading for 
MMSN-23 (17.5 and 4.53 mV respectively), whereas MMSN-2 are positive before 











potential of MMSN-2 is likely due to measuring the zeta potential of the pDNA (2 
µg/mL) and MMSN (80 µg/mL) in PBS without removing any unabsorbed pDNA. The 
authors interpreted the low zeta potential of MMSN-2 as the pDNA being 
electrostatically bound to the surface of MMSN-2, whereas it is successfully loaded into 
the pores for MMSN-23.3 However, at such a low zeta potential the negatively charged 
pDNA would repel one another without a countercharge on the surface of the particle, so 
the zeta potential reading was likely complicated by free pDNA in solution. 
 
 
Figure 3.3. Adsorption data for MMSN-2 and MMSN-23. A) Zeta potential of the two 
nanoparticle types before and after pDNA binding (80 µg/mg of MMSN). Zeta potential 
was measured in pH 7.4 buffer and pDNA was present at the time of measurement. B) Gel 
retardation assay with increasing amounts of MMSN. The amount of pDNA (pLuc) was 
kept constant at 0.5 µg. The MSN and pDNA were incubated for 1 hour prior to loading 
on the agrarose gel. C) Average amount of loaded plasmid based on gel assay fluorescence. 
Image modified from reference 3. 
  
The luciferase gene (pLuc) was then loaded into both formulations to determine 
the loading capacity. A gel retardation assay was then employed to determine the loading 
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capacity of the two particle types. The assay uses a gel through which the DNA/particle 
or free DNA travel under an electric field that separates them by weight. The gel 
retardation assay revealed that MMSN-23 had almost four times higher loading capacity 
based on the intensities on the gel (Figure 3.3.) where pDNA was imaged with a UV 
trans-illuminator. This is demonstrated quantitatively in Figure 3.3. (C) where 20 µg of 
MMSN-2 loaded 15 pDNA, while MMSN-23 loaded 36.6. 
Solberg and colleagues used an acid prepared mesoporous silica (APMS) 
nanoparticles to investigate the DNA loading capacity of 34 (APMS-34), 54 (APMS-54), 
and 100 (APMS-100) Å pores.4 The nanoparticles were prepared via the sol-gel method 
under acidic conditions, and the pores were varied by suspending the particles post 
synthesis and surfactant removal in NH4OH for different time periods.4 The benefits of 
APMS include a spherical shape, fast preparation (under 2 hours), and easily controllable 
particle size and pore diameter.4 The double-stranded calf thymus DNA (~2000 bp) was 
loaded via incubation and the DNA adsorption was measured at equilibrium using UV 
adsorption at 260 nm. Pore size comparison was made with Mg2+-doped APMS and 
modified with APTES (~2.2 mmol/g) (Figure 3.4.). When APMS was doped with Mg2+, 
APMS-54 demonstrated the highest adsorption capacity at 5.7 µg/mg. Solberg and 
colleagues hypothesized that the higher loading capacity of APMS-54 when compared 
to APMS-100 (4.3 µg/mg) was due to the amount of loaded cation, in turn correlated to 
the larger surface area of APMS-54.4 When APMS was functionalized with APTES, 
APMS-100 had the largest adsorption capacity at 15.7 µg/mg. This is almost three times 
larger than APMS-54 doped with Mg2+. The large adsorption difference between the two 
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can be explained by the more favorable direct electrostatic interaction between the 
cationic ammonium group covalently attached to APMS when compared with a metal 
cation that interacts with both the anionic silica and DNA.4 
 
 
Figure 3.4. The adsorption of DNA for three pore sizes, 34, 54, 100 Å. (A) The DNA 
adsorption when APMS was doped with Mg2+. A Langmuir fit, which assumes a monolayer 
on the surface of a homogenous surface, was used for the 54 and 100 Å materials. A 
Freundlich fit, which works well for heterogeneous surfaces and low adsorbate 
concentrations, was used for the 34 Å material. (B) The DNA adsorption when APMS was 
modified with amino linkers via APTES. A Langmuir fit was used for all three materials. 
Image adapted from reference 4. 
 
3.1.2. Loading siRNA 
Whereas DNA and pDNA can vary in size, siRNA is conventionally a 19 base 
pair duplex with a symmetric two base overhang on either strand on the end that 
terminates in a hydroxide group (termed the 3’ end).5 Longer RNAi duplexes (dsRNA) 
that are processed by enzymes in the cell into siRNA have been investigated as silencing 
agents and are usually 27 bp.5 
Na and colleagues used the same preparation method as Kim and colleagues to 
examine siRNA adsorption and delivery of MSNs with 2 nm pores (MSN2) and MSNs 
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with 23 nm pores (MSN23).6 Both were approximately 200 nm in diameter based on 
TEM measurements and were grafted with APTES to possess approximately 3.6 mmol/g 
of amines per gram of MSN.6 PEG was conjugated to the exterior to minimize corona 
formation and aggregates forming the final particles P-T-MSN23 and P-T-MSN2.  
Initially the study attempted to compare the two pore sized nanoparticles with the 
PEG exterior, but P-T-MSN2 loaded a negligible amount of siRNA based on gel 
electrophoresis data.6 The authors interpreted this as evidence that siRNA was adsorbing 
onto the surface of the MSNs and not in the pores, which is consistent with Kim and 
colleagues’ study with pDNA. Instead, the unPEGylated formulation (T-MSN2) was 
used. Zeta potential measurements before and after siRNA loading were consistent with 
DNA pore optimization studies; the zeta potential changed from 8.1 to -6.49 mV for T-
MSN2 and 19.4 to 2.54 mV for P-T-MSN23.6 The ability for the two formulations to 
protect siRNA against GFP (siGFP) was evaluated by first incubating the siRNA loaded 
particles in PBS with RNase for 1 and 2 hours. The siRNA was then detached from the 
particles by heparin, a highly polyanionic polymer that disturbs the electrostatic 
interactions between siRNA and the functionalized silica surface.3 Gel electrophoresis 
determined how much intact siRNA remained following this procedure (Figure 3.5.). At 
0 hours naked siGFP, T-MSN2 loaded with siGFP (siGFP+T-MSN2), and P-T-MSN23 
loaded with siGFP (siGFP+P-T-MSN23) have the same amount of intact siRNA. After 
1 hour both siGFP and siGFP+T-MSN2 no longer have intact siRNA, while siGFP+P-
T-MSN23 still releases intact siRNA. After two hours incubation, significant siRNA 
degradation occurred for P-T-MSN23, which is likely due to slow diffusion of the loaded 
genes from the pores.6 The additional protection by P-T-MSN23 may also be due to the 
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fact that it included PEG, since PEG has been shown to reduce protein adsorption and 
decrease oligonucleotide degradation.7  
 
 
Figure 3.5. Gel electrophoresis study examining siRNA protection by T-MSN2 and P-T-
MSN23 when loaded with green fluorescent protein siRNA (siGFP). At 0 hours, naked 
siGFP, siGFP+T-MSN2, and siGFP+P-T-MSN23 have a strong signal due to the siRNA 
not being degraded by the RNase. After 1 hour, the naked siRNA and loaded in the T-
MSN2 has been degraded, while P-T-MSN23 continues to have a signal. After 2 hours, the 
signal from the P-T-MSN23 system has diminished. Image modified from reference 6. 
 
A later study by Kim and colleagues compared 2, 4, 7, and 10, and 23 nm pore 
base prepared, amine decorated MSN for siRNA loading.8 The intermediate pore sizes 
were synthesized using different amounts of TMB. Surfactant was removed using 
ethanolic hydrochloric acid solution. Based on TEM images, the MSNs were 
approximately 200 nm and pore expansion resulted in an increased pore volume and 
decreased surface size based on nitrogen adsorption isotherms.8 The MSNs were amine 
functionalized by APTES (3.1-3.6 mmol/g). Zeta potentials before and after siRNA 
adsorption reveal a sharp decrease for MSN2 and MSN4 (Figure 3.6. (A)). This is 





Figure 3.6. A) Comparison of zeta potential before and after siRNA loading. B) Gel 
retardation assay investigating siRNA release (top) and protection against RNase 
(bottom).8 Image modified from reference 8. 
 
Two gel retardation assays determined slightly better protection from RNase for 
MSN10 compared to MSN7 and MSN23 (Figure 3.6. (B)). In the first procedure without 
RNase, the particles were loaded and then the siRNA was released using heparin. The 
naked siRNA, MSN2, MSN4, MSN10, and MSN23 released intact siRNA that traveled 
the length of the gel. MSN7 did not release a discernable amount of siRNA, possibly 
because it was energetically favorable for siRNA to remain in the pores due to their size.8 
In the second study, the loaded particles were first incubated with RNase in buffer and 
then the remaining intact siRNA was released from the pores with heparin. Like the 
naked siRNA, both MSN2 and MSN4 produced no signal because of siRNA degradation, 
further suggesting external attachment. MSN7 protected and released some siRNA, while 
a portion remained in the pores like before and, consequently, does not travel on the gel. 
MSN10 and MSN23 both protect their loaded siRNA from RNase and successfully 
release it upon treatment with heparin. 
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The five different MSN were then loaded with siRNA targeting vascular 
endothelial growth factor (siVEGF) and incubated with a breast cancer cell line (MDA-
MB-231). VEGF is upregulated in cancer and allow tumors to grow and metastasize. 
Knockdown efficiency was measured at 48 and 96 hours post transfection. Gene 
expression levels were evaluated by using reverse transcription polymerase chain 
reaction (RT-PCR) to synthesize complementary DNA (cDNA) from the messenger 
RNA (mRNA) of the targeted protein and amplify that gene. Then gel electrophoresis 
was used to detect the amount of cDNA present where the greater signal indicated more 
of the specified mRNA (Figure 3.7.). The expression of VEGF was compared to 
GAPDH (GDH), a housekeeping gene, as a control.8 MSN10 demonstrated the most 
efficient knockdown at the two time points. MSN7 increased knockdown efficacy at 96 
hours when compared to its efficiency at 48 hours, while MSN23 exhibited greater 
knockdown efficacy at 48 hours when compared to its results at 96 hours. These results 




Figure 3.7. Investigation of VEGF gene knockdown dependent on pore size and incubation 
time. A) Gene expression levels at 48 and 96 hours measured by gel electrophoresis. B) 
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The band intensities from the gel electrophoresis were normalized and compared to GDH 
expression. Image modified from reference 8. 
 
Steinbacher and colleagues similarly found pore sizes larger than 4 nm were 
optimal for siRNA loading and release. Using APMS externally functionalized with 
tetraethylene glycol (TEG) and internally with 1-(3-trimethoxysilylpropyl)-
diethylenetriamine (DETA) (Figure 3.8.), Steinbacher’s group compared three pore 
diameters (4, 8, 15 nm) and three different percent functionalizations of DETA (0.5, 2.5, 




Figure 3.8. Modification of the interior of APMS. TEG is first conjugated to the exterior, 
followed by surfactant extraction via acid reflux. DETA is then attached to the interior by 
stirring rapidly for ten minutes. The particles are then filtered and then cured at 80 °C for 
18 hours. Image modified from reference 9. 
 
DETA/TEG functionalized APMS was loaded by incubating siRNA with APMS 
in a buffer. Release was then measured by stirring the siRNA loaded NPs in cell culture 
medium at 37 °C. Both loading and release were measured with UV/Vis. The amount of 
DETA functionalization was found to have  a substantial impact on the release efficiency 
for 8 and 15 nm pores.9 Release kinetics found that 8 nm pores with 15% DETA 
functionalization released the largest amount of siRNA per APMS, while 8 nm pores 
































Figure 3.9. Graphs showing the specific release (top) and fraction release (bottom) of 4, 8, 
and 15 nm pores with either 0.5%, 2.5%, or 15% DETA functionalization. The largest 
amount of siRNA was released by 8 nm pores with 15% DETA, while the most efficient 
was 8 nm pores with 0.5% DETA Image modified from reference 9. 
 
 
3.2 Additional large pore synthesis methods 
While both acid and base catalyzed MSN can undergo pore enlargement with 
either the swelling agent TMB or acid etching with ammonium hydroxide, these methods 
can result in structural instability. Thus, other methods have been explored to synthesize 






3.2.1. Variations on sol-gel method 
Wu and colleagues synthesized a small MSN with larger pores by adding a silica 
precursor with a hydrophobic group. They used bis[3-(triethoxysilyl)propyl]tetrasulfide 
(BTES) in addition to TEOS to form the silica nanoparticle.10 BTES co-hydrolyzes and 
co-condenses with TEOS and produces larger pores due to its hydrophobic –
CH2CH2CH2-S-S-S-S-CH2CH2CH2- group can penetrate into the hydrophobic micelles 
(Figure 3.10.).10 Micelles were formed by CTAC to direct the structure and the base 
catalyst was triethanolamine (TEA). The final particles have a diameter of ~30 nm 
determined by TEM and a 50.75 nm diameter based on DLS measurements.10 Nitrogen 
sorption data determined the conical pores have an average diameter of 6.2 nm (Figure 




Figure 3.10. The addition of BTES is thought to cause the CTAC micelles to become 
enlarged due to the long hydrophobic chain between the two silica groups. The final 
particles are approximately 30 nm in diameter as measured by TEM (right image). Image 





Figure 3.11. Nitrogen sorption isotherm of Wu and colleagues’ small MSN is consistent 
with well-defined, monodispersed pores. The inset demonstrates the pore distribution (red 
arrow), whereas the larger pore reading is likely due to capillary action between particles. 
Image adapted from reference 10. 
 
3.2.2. Microemulsion templating 
Microemulsion templating was first described by Carroll and colleagues as a 
method to create MSNPs with both larger and smaller pores.11 Ashley and colleagues 
then used this emulsion processing technique to form large pore MSNPs (3-13 nm and 
23-30 nm pores determined by nitrogen physisorption) for siRNA delivery.12 
Microemulsion templating uses two surfactants, a nonionic surfactant (Abil EM 90) that 
forms the oil phase and a cationic surfactant (CTAB) that is only soluble in the aqueous 
phase.11 TEOS is the silica precursor and is hydrolyzed in an acidic solution. By stirring 
the system, micrometer sized aqueous emulsion droplets (containing TEOS) form in the 
oil phase and are stabilized by Abil EM 90.11 These emulsion droplets direct the 
microemulsion formation by CTAB around which the TEOS condenses.13 Because 
CTAB is above the critical micellization concentration, the micelles form within the 
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aqueous phase to produce pores.11 Once the solvent is removed, a bimodal porous 
network is produced. The pores are larger on the exterior of the particle (23-30 nm) due 
to being formed by both surfactants and smaller on the interior (3-13 nm) due to 
consisting mainly of CTAB (Figure 3.12.).11 
 
 
Figure 3.12. Schematic of microemulsion technique. A) Emulsion droplets form in Abil 
EM 90, the oil phase (dark grey). B) A single aqueous droplet containing microemulsion 
droplets (dark grey) and micelles (red). C) Oil/water interface that is absorbing both 
surfactants causing a drop in the interfacial tension. Image modified from reference 11. 
 
After undergoing size separation, the final particles had an average particle 
diameter of 165 nm based on DLS (Figure 3.13.). Nitrogen sorption is consistent with 
the presence of larger and smaller pores. The BET surface area was 850 m2 g-1 with a 





Figure 3.13. Physical characterization of unmodified microemulsion MSNPs. A) TEM 
image of the bare silica mesoporous nanoparticle formed by microemulsion technique. The 
scale bar = 100 nm. B) DLS after size based separation. Final particles had a diameter of 
~165 nm. C) Nitrogen sorption isotherm of size separated MSN. The hysteresis is 
consistent with a network of larger pores connected by smaller pores. D) Pore volume plot 
calculated from the adsorption branch of the isotherm using Barrett-Joyner-Halenda model. 




3.3 Modifications for efficient delivery 
Once the base silica particle is synthesized and optimized for oligonucleotide 
loading and delivery, the exterior must be optimized for delivery. Exterior 
functionalization often includes increasing biocompatibility with PEG, including a 





3.3.1. Polymer exterior 
As discussed previously, PEI and PEG are used due to their ability to cause 
endosomal escape and increase circulation times respectively. A PEI exterior without 
PEG has been utilized by several groups, with varying results. Finlay and colleagues used 
a base catalyzed method to create an siRNA delivery system. In the group’s procedure, 
CTAB was used as a surfactant, sodium hydroxide as the base, and TEOS as the silica 
precursor. Shortly after particle formation 3-(trihydroxysilyl)propyl methylphosphonate 
was added to prevent interparticle aggregation.14 The final NPs were smaller than 127 
nm in diameter and had an average pore diameter of 2.5 nm, both determined by TEM.15-
16 Acidic methanol was used to remove the surfactant. The PEI coating (1.8 kDa) was 
added to the MSNs by suspending the particles in PEI and ethanolic solution. 
Electrostatic attachment occurs between the weakly charged PEI and the negatively 
charged silica surface, since PEI may adjust its charge density in the absorbed layer to 
compensate for the electrostatic potential at the surface.17  
After attaching the short chain PEI, the system was loaded with siRNA by 
incubation.15-16 Because siRNA has a diameter of 2.6 nm, it is possible that siRNA adopts 
the necessary orientation to enter the pores. However, the authors note this is unlikely, 
since PEI coats both the particle’s interior and exterior.16 The nanoparticle successfully 
bound with siRNA and could protect it from cleavage by RNase-A after 1 hour 
incubation (Figure 3.14.).16 The nanoparticle system was loaded with siRNA targeting 
TWIST1, a transcription factor whose reactivation increases cancer cell ability to self-
renew, survive, and metastasis.15 Intravenous treatment of TWIST1 siRNA demonstrated 
62 
 
tumor size reduction but no reduction in metastatic lesions.15 This may be due to the lack 
of targeting ligand that would aid in delivery to cancer cells that have not yet developed 
pathological vasculature with enhanced permeability.18 
 
 
Figure 3.14. Gel electrophoresis post incubation with RNase-A demonstrates that PEI 
functionalized MSN can protect siRNA from RNase-A cleavage. Lane 1 shows gel 
migration of free siRNA. Lane 2 is the result of siRNA after RNase A treatment. Lane 4 
shows that siRNA bound to MSNs remain in the gel wells and was not degraded by the 
RNase A. Lane 5 and 7 demonstrate some siRNA dissociation but not degradation. Image 
adapted from reference 16. 
 
Na and colleagues demonstrated successful in vivo delivery of siRNA affecting 
vascular endothelial growth factor (siVEGF) in MDA-MB-231 xenographs with an 
amine (3.6 mmol g-1) and PEG decorated MSN. The base prepared silica nanoparticle 
had 23 nm pores expanded with TMB and a diameter of 250 nm based on TEM images. 
The amine was then conjugated to the silica surface using APTES upon which PEG was 
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conjugated (siVEGF-P-T-MSN23). The siRNA loaded MSNs were intratumorally 
injected four times over a period of 20 days. Intratumor injection was chosen due to the 
aggregation tendency of the particles.6 After thirty days the excised tumors weighed 240, 
190, and 52 mg after being treated with PBS, naked siVEGF, and siVEGF-P-T-MSN23 
(Figure 3.15.).  
 
 
Figure 3.15. A) The three excised tumors after treatment with PBS, naked siVEGF, and 
siVEGF-P-T-MSN23 for twenty days. Tumors were extracted on day 30. The siRNA 
loaded MSNs reduced tumor volume. B) VEGF mRNA was significantly downregulated 
in the tumor treated with siVEGF-P-T-MSN23 compared with the other two treatment 
groups. Image adapted from reference 6. 
 
3.3.2. Amino acid functionalization 
As of yet, the only publication on amino acid functionalization as a biocompatible 
exterior for efficient oligonucleotide delivery has been poly-L-lysine (PLL). Hartono and 
colleagues contrasted the effectiveness of PLL with an amine exterior.19 The silica 
particle was synthesized using a two surfactants, triblock copolymer (F127) and a 
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fluorocarbon surfactant (FC-4), TMB, and TEOS as the silica precursor in acidic 
conditions.19 The final MSN had a particle diameter between 100-200 nm and an average 
13.4 nm pore entrance and 27.9 nm cavity.19 Amine attachment was performed with 
APTES, while PLL functionalization was achieved by first grafting an epoxy silane (3-
GPS) to the interior and exterior surfaces. PLL was then attached through a nucleophilic 
addition to the epoxide on 3-GPS.19 The final particles retained large pore cavities and 
entrances, as well as having a similar positive zeta potential (Table 3.1.). 
 















Amine 155 0.63 24.6 11.3 3.23 
PLL 171 0.64 24.1 11.8 1.90 
 
Both modifications adsorbed similar amounts of oligo DNA (21-nucleotides long 
conjugated with cyanine dye Cy3), although PLL resulted in higher cellular uptake 
(Figure 3.16.). While PLL decorated MSN are taken up by cells more efficiently, 
cytotoxicity studies performed using the cervical cancer cell line SiHa found PLL to be 
more toxic than both the bare MSNP and amino functionalized nanoparticle. The authors 
attribute this to the primary amine surface groups that induce toxicity due to strong 
interactions with the cell membrane (which also leads to increased cell uptake).19 The 
exact mechanism of PLL’s cytotoxicity is poorly understood, however it is thought to be 
for the same reasons as higher weight PEI.20 Thus, cytotoxicity may be reduced if a lower 





Figure 3.16. Cell uptake by HeLa cells was determined by labeling DNA with Cy3. Both 
the free DNA (DNA-Cy3) and bare silica MSNs (LP-MSNs) result in no Cy3 signal. The 
amine decorated MSN (LP-MSN-A) resulted in a positive signal. The PLL decorated MSN 
(LP-MSN-P) has a much higher signal and, thus, a higher transfection. Image modified 
from reference 19. 
 
Delivery of siRNA was then measured based on cell viability by delivering 
siRNAs against polo-like kinase 1 (PLK1) and minibrain-related kinase (Mirk) to 
osteosarcoma cell line KHOS. Both PLK1 and Mirk are highly expressed in 
osteosarcoma cells and silencing them can inhibit cell growth.19 The control was siRNA 
S10, an siRNA effective against the human papillomavirus (HPV) type 16 E6 gene.19 
Amine decorated MSN (LP-MSN-A) successfully delivered both PLK1 and Mirk siRNA 
and effected significant decrease in cell viability at high siRNA concentrations (100 nM) 
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(Figure 3.17.).19 PLL decorated MSN (LP-MSN-P) delivering PLK1 siRNA also caused 
a decrease in cell viability at high siRNA concentrations (100 nM). The difference 
between the two modifications, amine and PLL, were 15% and 30% respectfully. 
Although PLL modified MSNPs resulted in a higher reduction of cellular viability, this 
result is complicated by the higher cellular uptake and toxicity of PLL (10%) when 
compared to the amino functionalization (5%).19 
 
 
Figure 3.17. LP-MSN-P and LP-MSN-A were loaded with siRNAs targeting PLK and 
Mirk that were overexpressed in the osteosarcoma cell line KHOS. Three siRNA loading 
concentrations were tested (25, 50, 100 nM), and the positive control was the cell viability 
without any treatment. Another siRNA , S10, was used as a negative control. A) LP-MSN-
P; B) LP-MSN-A. Image modified from reference 19. 
 
3.3.3. Cell penetrating peptides 
First discovered in 1988, cell penetrating peptides can trigger cell internalization 
into the cytoplasm of cell and direct its intracellular delivery.21 Cell penetrating peptides 
are generally less than 30 amino acids and are derived from both natural or unnatural 
protein sequences.21 They are easily attached to MSN delivery systems by conjugating 
the peptide to the outer covering (such as PEI). 
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Wu and colleagues used transcription-transactivating (Tat) protein for their 
nucleus targeting MSN system. Tat was first discovered on HIV-1, allowing the virus to 
enter cells and translocate into the nucleus.21 The silica nanoparticles were synthesized 
using a modified sol-gel method as described previously where both BTES and TEOS 
were silica precursors.10 The MSN had a TEM diameter of approximately 30 nm and 
pores with a diameter of 8-13 nm, which the group termed MONs.10 The MONs were 
then functionalized first with an amine via APTES, then reacted with succinic acid to 
produce MONs-COOH, and finally with PEI (1.2 kDa) resulting in MONs-PEI (Figure 
3.18.). The cell penetrating moiety TAT peptide was grafted onto the surface by an 
esterification reaction (MONs-PTAT), leaving free amines on the PEI to load the pDNA. 
The final particle had a DLS average diameter of 91.28 nm and a positive zeta potential 
of 40.6 mV (Figure 3.19.). pDNA was then loaded by vortexing.10 
 
 
Figure 3.18. The pores and exterior of the small MSN were first functionalized with 
APTES. Succinic acid was then used to attach a carboxylic acid. PEI was conjugated to 
this exterior, followed by TAT. Finally, pDNA was loaded into the pores. Image modified 





Figure 3.19. A) DLS particle size distribution after each modification step. B) The zeta 
potential measurement after each modification step. Image modified from reference 10. 
 
The final delivery vehicle MON-TAT demonstrated successful internuclear 
accumulation and high transfection efficiency in vitro when compared to MON-PEI in 
HeLa cells (Figure 3.20.). The group used confocal fluorescence laser scanning 
microscopy (CLSM) to track MONs-PTAT with green fluorescence (FITC) to determine 
the uptake and particle location. The CLSM studies demonstrated that TAT decorated 
MSN had a higher cellular uptake and accumulation in the nucleoplasm.  
 
 
Figure 3.20. Cellular and nuclear uptake amounts of MONs-PEI and MONs-TAT by HeLa 




Transfection efficiencies were evaluated by loading MON-PEI and MON-PTAT 
with pEGFP, pDNA encoding for enhanced green fluorescent protein, and incubating 
with HeLa cells. Both fluorescent intensity and the proportion of cells exhibiting EGFP 
expression were calculated (Figure 3.21.). The significantly higher transfection efficacy 




Figure 3.21. Tranfection efficacy of MON-PEI and MON-PTAT when loaded with 
pEGFP. A) Fluorescent images of EGFP expression. B) Fluorescence intensity and C) 
percentage of cells exhibiting EGFP expression (n = 3, *p < 0.05 and **p < 0.01). The 
mass ratio is nanoparticles to pDNA. Image modified from reference 10. 
 
3.3.4. Ligand mediated targeting 
To direct in vivo delivery of an MSN system, affinity ligands can be used to 
specify uptake and retention by particular cells. Ligands are usually an antibody or 
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peptide in cancer delivery and are selected that bind to molecules or receptors 
overexpressed on a cancer cell line. Affinity is only increased once the delivery system 
is in close enough proximity to the targeted tissue.22 This strategy of active targeting can 
also selectively deliver therapies for other applications where the intended cell type has 
unique receptors not found on other cells.23 
Ashley and colleagues developed a system with the targeting peptide SP94 that 
binds specifically to hepatocellular carcinoma cells, as well as the membrane fusion 
peptide H5WYG. The silica nanoparticle was prepared via the microemulsion templating 
described in section 3.2.2. The final MSN had an average diameter of 165 nm with 23-
30 nm pores and 3-13 nm pores. After removing the surfactant via calcination, the silica 
was modified with 3-[2-(2-aminoethylamino)ethylamino]propyltrimethoxysilane 
(AEPTMS) to decorate the silica surface with amines. Cationic liposomes composed of 
1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), and cholesterol were synthesized with a Mini Extruder set.12 
They were then attached to the particles’ surfaces by incubating the MSNs with 2- to 4-
fold volumetric excess of liposomes.12 The liposome fusion to the MSN’s exterior is 
electrostatic and occurs when the MSN diameter is greater than 30 nm.24 The final 
system, termed DOPC protocells, were separated from the excess lipid via centrifugation 
(Figure 3.22.).12 Peptides SP94 and H5WYG were conjugated to primary amines present 





Figure 3.22. Schematic of the final protocell where the silica core loads siRNA and 
supports an external lipid bilayer. The exterior of the lipid is functionalized with the 




Figure 3.23. Peptides SP94 and H5WYG were conjugated to the primary amines in lipid 
head groups by using the crosslinker SM (PEG)24. 
 
Protocells protect and retain their cargo until reaching an acidic pH that triggers 
release (Figure 3.24.). This ability was determined by examining the rate at which DOPC 









































acidic conditions present in tumor cells.12 Both DOPC and DOTAP lipid nanoparticles 
(LNPs) were tested in order to determine the improved protection and delivery of DOPC 
protocells. Under pH 7.4 DOPC protocells released very little of their cargo over 72 
hours, while DOTAP LNPs lost approximately 50% and DOPC LNPs lost 100%. At pH 
5 DOPC protocells released their cargo over 24 hours. DOPC and DOTAP LNPs released 




Figure 3.24. The rates at which DOPC protocells, DOPC LNPs, and DOTAP LNPs release 
their siRNA cargo under pH 7 (left) and pH 5 (right). Figure modified from reference 12. 
 
In order to confirm targeted delivery of siRNA in vitro, protocells were loaded 
with an equimolar mixture of siRNAs targeting proteins involved in the regulation of the 
cell cycle regulating cell growth and viability: cyclin A2, cyclin B1, cyclin D1, and cyclin 
E.12 Protein expression in treated cells were measured by Alexa Fluor 488 antibody 
labeling and then flow cytometry analysis that counts the labeled proteins.12 The group 
found that by increasing the concentration of protocells there was a dose-dependent 
decrease in the protein levels of each of the targeted genes (Figure 3.25. (A)). When 125 
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pM of siRNA loaded in protocells was incubated with a type of hepatocellular carcinoma 
cells (Hep3B), the targeted proteins were repressed by nearly 90% after 72 hours (Figure 
3.25. (B)).12 Protocells demonstrated superior efficiency when compared with SP94 
targeted DOTAP lipid nanoparticles (Figure 3.25. (C)). While DOTAP lipid 
nanoparticles loaded with the same amount of siRNA (125 pM) caused ~60% repression 
in cyclin A2 expression in Hep3B, 300-fold fewer protocells were needed to reduce 
cyclin A2 expression by 90%. 
 
 
Figure 3.25. A) Dose dependent decrease in the expression of cyclin A2, B1, D1, and E 
protein as well as cyclin A2 mRNA in Hep3B cells after exposure with siRNA loaded, 
SP94 targeted procells. Cells were incubated for 48 hours. B) Time dependent decrease in 
the expression cyclin A2, B1, D1, and E protein as well as cyclin A2 mRNA in Hep3B 
cells after exposure with 125 pM siRNA for various periods of time. C) The left axis shows 
the percentages of initial cyclin A2 protein after exposure with protocells (DOPC 
protocells) and DOTAP lipid nanoparticles. The right axis illustrates the number of 
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particles required to reduce cyclin A2 expression by 90%. Image modified from reference 
12. 
 
3.3.5. Triggered release 
Triggered release systems exploit either the lower pH or larger number of 
reducing agents in cancer cells when compared to normal tissue. Thiol based redox 
triggered mechanisms use the large difference in GSH concentration found in normal 
tissue (1-10 mM) and blood (2 µM) compared to tumor cells where GSH concentration 
is 7 to 10 times higher.1 Human tumors also are more acidic than normal tissue and have 
exhibited pH states ranging from 5.7 to 7.8.25 This is partly due to rapid growth and lactic 
acid accumulation, termed Warburg’s effect, as well as insufficient blood supply and 
poor lymphatic drainage.25 Harnessing pH-triggered delivery is challenged by the rapid 
pH drop following endocytosis to pH < 6.0, because the system may release the cargo in 
the endosome rather than the cytosol.25 Consequently, techniques to escape the endosome 
via the proton sponge effect as well as triggered release are necessary.  
Lin and colleagues created a redox triggered delivery system using a base 
prepared MSN with TMB widened pores.26 The final MSN had a diameter of 100-150 
nm based on TEM, and a pore diameter of 10 nm based on Nitrogen sorption data.26  
The polymer was attached to the silica walls by adsorption of vinyl monomers, 
cross-linkers, and radical initiators via wet-impregnation method (Figure 3.26.).27 The 
monomer, dimethylaminoethyl methacrylate (DMAEMA), N,N’-(dithiodi-2,1-
ethanediyl)bis(acrylamide) (BAC) cross-linker, and a,a-azoisobutyronitrile (AIBN) 
radical initiator were dissolved in ethanol and incorporated into the walls of the MSN via 
the wet-impregnation method. Reduced pressure is then used to ensure uniform 
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distribution, followed by polymerization via heating to form a uniform polymer 
coating.27 The final MSN (ssCP-MSN) still had a pore diameter of 10 nm with a reduced 
pore volume (0.63 cm3 g-1) and BET surface area (159 m2 g-1) (Figure 3.27.).26 The final 
average hydrodynamic diameter was 141.8 nm, and the cationic polymer modification 
produced a positively charged nanoparticle with a 27.1 mV zeta potential.26 The ssCP-
MSN/siRNA complex (30 ssCP-MSN:1 siRNA ratio) continued to have a positive zeta 
potential of 24.6 mV.26  
 
 
Figure 3.26. (A) First the DMAEMA monomer, BAC cross-linker, and AIBN radical 
initiator mixture is adsorbed onto the surface of the MSN. (B) After drying to remove the 
ethanol, polymerization was performed to result in thermal polymerization.26-27 Image 
modified from reference 27. 
 
Protection and release studies demonstrated siRNA was protected against 
exchange with low concentrations of negatively charged heparin. This could be due to 
the high weight ratio between the positively charged particles and siRNA (30 ssCP-MSN: 
1 siRNA). The heparin may be interacting with the free positively charged particle 
surface before displacing the siRNA. Dithiothreitol (DTT), a reducing agent used to 




Figure 3.27. A) TEM images of the 2 nm pore base prepared MSN (MSN2), the 10 nm 
pore enlarged MSN (MSN10), and the modified MSN (ssCP-MSNs). B) BET surface area, 
pore volume, and pore size for the three particle types. Image modified from reference 26. 
 
caused siRNA release when examined with gel electrophoresis (Figure 3.28.). While 
DTT is a strong reducing agent, cancer cells have 7 to 10 times higher the GSH 
concentration than normal cells (1-10 mM).1 Thus, this concentration of DTT likely 
mimics the increased reduction potential in cancer cells. However, other studies employ 
GSH to more closely mimic the reduction potential in cancer cells.28 
The loaded ssCP-MSNs successfully silenced luciferase in vitro (Figure 3.29.), 
but were unable to reduce tumor growth in vivo. In vitro gene silencing was also less 
than transfection by siRNA loaded Lipofectamine 2000. Upon tail vein injection, ssCP-
MSNs/siRNA accumulated in the liver, lung, spleen, and kidney as determined by 
confocal microscopy of tissue samples, indicating the MSNs were mainly taken up by 
the RES.26 This indicates PDMAEMA does not offer increased circulation time and RES 
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escape found with PEG. The ssCP-MSN/siRNA complexes were also found in the 
adrenal gland, heart, and thymus.26 
 
 
Figure 3.28. A) Zeta potential for ssCP-MSNs after being stored in water with and without 
10 mM DTT. After four hours in water the zeta potential dropped from 27.1 mV to 25.3 
mV. In water with DTT the zeta potential dropped to 14.9 mV. This is attributed to the 
PDMAEMA separating from the surface of the ssCP-MSNs after cleavage of the disulfide 
linkages. B) Gel electrophoresis of ssCP-MSN/siRNA complexes (30:1 w/w) treated with 
heparin with/without DTT. DTT treatment at higher concentrations resulted in is migration 
similar to free siRNA. Image modified from reference 26. 
 
 
Figure 3.29. Luciferase expression silencing in HeLa-Luc cells after treatment with either 
Lipofectamine 2000/siRNA complex or ssCP-MSN/siRNA complexes at different w/w. 
The negative control is untreated HeLa Luc cells. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 




Sun and colleagues similarly used a base preparation method that was followed 
by enlarging the pores with TMB to build a redox responsive system.1 The synthesized 
MSNs had an average diameter ~160 nm based on TEM measurements and the nitrogen 
sorption isotherm found a BET surface area of 771.65 m2 g-1, a pore diameter of 5.7 nm, 
and pore volume of 1.67 cm3 g-1.1 After the surfactant was removed via acidic ethanolic 
solution, siRNA was loaded under dehydrated conditions with a salt solution (guanidine 
hydrochlorine) that disrupts the hydrogen between water molecules (i.e. chaotropic). The 
high concentration of ions enable loading by decreasing the debye length and shield silica 
and DNA’s negative charges, which weakens the repulsive electrostatic force between 
DNA and the silica surface.29 The loaded particles were then suspended in PEI (2kDa) 
ethanol solution to cap the particles with PEI (MSN-siRNA/PEI). PEI was then 
crosslinked by disulfide bonds by using dithiobis(succinimidyl propionate) (DSP) to 
create the triggered release system (Figure 3.30.). The final MSN-siRNA/PEI complex 

















































Figure 3.31. A) Bare particles with the surfactant removed. B) siRNA is loaded into the 
pores in a chaotropic salt solution. C) PEI is attached to the surface to cap the pores, 
facilitated delivery, and protect the siRNA. D) The disulfide linker DSP is conjugated to 
PEI to create a redox triggered delivery system. E) The zeta potential of the bare MSN, 
MSN-siRNA/PEI, and with the DSP linker (MSN-siRNA/CrPEI. F) siRNA release study 
of MSN-siRNA/CrPEI and MSN-siRNA/PEI in phosphate buffer solution (PBS) at pH 7.4. 
Image modified from reference 1. 
 
MSN-siRNA/CrPEI successfully released its cargo under redox conditions while 
otherwise retaining it under neutral conditions (Figure 3.31.). DTT is a redox agent that 
simulates exposure to GSH.1 Without the disulfide linker, siRNA is not contained in the 
MSN and leaves through diffusion. Compared to other systems where PEI is conjugated 
in the pores, MSN-siRNA/PEI diffusion is more rapid, since PEI is attached following 
siRNA loading. Capping with DSP significantly reduces siRNA release compared to 
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MSN-siRNA/PEI. Upon the addition of DTT a burst release is seen and the overall 
release exceeds MSN-siRNA/PEI. 
Both in vitro and in vivo delivery significantly downregulated the targeted protein 
VEGF when compared with the control group, cells treated with serum free medium, and 
MSN-siRNA/PEI (Figure 3.32.). Two types of siRNA were used to treat KB cancer cells, 
a subline of the keratin-forming tumor cell line HeLa: siRNA targeting VEGF (siRNA) 
and scrambled siRNA (siNC). The KB cells exhibited a 40% decrease (P < 0.05) in 
VEGF protein expression after treatment with MSN-siRNA/PEI and a 75% decrease (P 
< 0.01) after MSN-siRNA/CrPEI treatment.1 Protein expression was determined with a 
BCA Protein Assay Kit. The mRNA expression was measured with an ELISA and 
quantitative real time PCR to confirm VEGF expression was reduced by VEGF siRNA.1 
The mRNA levels were consistant with the protein expression levels in that MSN-
siRNA/CrPEI caused a greater downregulation of mRNA than MSN-siRNA/PEI, naked 
VEGF siRNA, and MSN-siNC/CrPEI.1 
 
 
Figure 3.32. A) The VEGF/BSA protein level for KB cells treated with free siRNA, MSN-
siRNA/PEI, and MSN-siRNA/CrPEI. The control is serum free medium. B) The VEGF 
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mRNA for KB cells treated with free siRNA, MSN-siRNA/PEI, MSN-siRNA/CrPEI, and 
MSN-siNC/CrPEI. Image modified from reference 1. 
 
The in vivo tumor growth inhibition study on nude mice bearing a KB xenograft 
tumor similarly found a significant inhibition of the VEGF protein of 46% (P < 0.05) 
when treated with MSN-siRNA/CrPEI compared with the control, injections with 5% 
glucose (Figure 3.33.).1 Injections were performed peritumorally.1 The intratumoral 
VEGF mRNA level was also significantly reduced between the two groups.1 In addition, 
the treated group demonstrated a significant reduction in CD31-positive tumor vessels 
and increased blood flow when investigated by immunofluorescent staining.1  
Li and colleagues combined these triggering strategies to create a pH and redox 
triggered system. The silica MSN were synthesized by means of a soft-templating 
method using triethanolamine (TEAH3), cetyl-trimethylammonium tosylate (CTATos), 
and tetraethyl orthosilicate (TEOS).30 The benefit of this synthesis method is a small, 
monodisperse diameter (80-110 nm) and large pores (15-23 nm) as determined by TEM 
 
Figure 3.33. Left- The level of VGSF/BSA protein in KB tumors after treatment with 5% 
glucose (control) and MSN-siVEGF/CrPEI (dose of siRNA 1.00 mg kg-1). Right- The level 





measurements.30-31 After removing the surfactant via acid reflux, APTES was then 
attached. Mercaptopropionic acid was then attached to the amine groups (Figure 3.34.). 
Finally, 2-(2-Pyridinyldithio)-ethanamine hydrochloride was attached to produce a 
highly positive charged surface for loading and a redox and pH sensitive coating to 
trigger release.30 Nitrogen sorption measurements revealed the final system (CMSN-A) 
had a BET surface area of 481 m2 g-1, 21 nm pore diameter, and 1.42 cm3 g-1 pore volume. 
 
 
Figure 3.34. Functionalization of Li et al.’s MSN. The amine functionalized particles (both 
within the pores and exterior) are reacted with Mercaptopropionic acid. 2-(2-
Pyridinyldithio)-ethanamine hydrochloride is then attached to the free sulfide group to 
produce a pH and redox responsive section. Due to the lower pH in cancer cells (pH 6.5 
compared to pH 7.4 in normal tissue) and acidic endosome (pH 5-6) and lysosome (pH 4.5-
5) in tumor cells, the positive moiety electrostatically bound to the loaded gene are released 
and the cargo is delivered. Image modified from reference 30. 
 
Agarose gel electrophoresis demonstrated that CMSN-A could load and protect 
pDNA from DNase1 degradation (Figure 3.35.). DNA was visualized on UV trans-
illuminator.30 DNase degradation is confirmed by comparing lane 1 (pDNA) and lane 2 
(pDNA and DNase1). The pDNA loaded CMSN-A remain in the gel wells (lane 3) even 



























the reducing agent DTT that is used to simulate the effects of GSH in vivo1 (lane 5), the 
pDNA was released, confirming the efficacy of the redox release mechanism.30 
Subsequent treatment by DNase1 of the DTT treated system resulted in pDNA 
degradation (lane 6) that confirms the previous protection in lane 4.30  
 
 
Figure 3.35. Agarose gel electrophoresis demonstrating the pDNA protection provided by 
CMSN-A. The amount of pDNA (1 µg) and CMSN-A (40 µg) were constant. Figure 
modified from reference 30. 
Gene transfection experiments confirmed the ability for CMSN-A loaded with 
pDNA to enter cells and deliver its genetic cargo. The gene pGFP was delivered to HeLa 
and 293-T cell lines (Figure 3.36.). Compared to the negative control (free pGFP), the 
CMSN-A delivery system successfully delivered its cargo, evidenced by the expression 
of the green fluorescent protein coded by pGFP. However, the positive control, 





Figure 3.36. Gene transfection study demonstrating the successful delivery of pGFP by 
CMSN-A. Image modified from reference 30. 
 
 
3.4 Chapter conclusions 
MSN based delivery systems are a promising platform for oligonucleotide 
delivery due to their high surface area and ability to internalize cargo in their pores when 
compared to solid silica nanoparticle systems. The first obstacle for MSN is optimizing 
the pores for DNA or RNAi loading. Current studies comparing pore sizes for DNA and 
pDNA indicate large pores are necessary (10 nm for ~2 kbp DNA and 23 nm for 4.8 kbp 
pDNA).3-4 Intermediate size pores (8-10 nm) were found by two groups to be optimal for 
siRNA loading and release.8-9 Only one group, Steinbacher and colleagues, investigated 
how the percent of pore functionalization influenced siRNA loading and release. They 
discovered the percent of pore functionalization could be optimized, indicating an 
important parameter that should be analyzed in future studies. 
Aside from pore expansion with TMB or etching with ammonium hydroxide, two 
main techniques have been explored to produce MSN with large pores and variable 
particle diameter. Wu and colleagues synthesized a small MSN (50.75 nm based on DLS) 
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with ~6.2 nm pores by adding another silica precursor, BTES, to co-condense with 
TEOS.10 Ashley and colleagues used microemulsion templating to produce 165 nm 
particles based on DLS with smaller and larger pores (approximately 3-13 nm and 23-30 
nm).12 
Several modification techniques have been investigated, although the lack of 
comparison within many of the studies to a benchmark result in difficulty comparing 
efficacy.32 Amine and PEG modified MSN with large 23 nm pores demonstrated in vivo 
tumor size reduction, but the particles had to be injected intratumorally due to their 
aggregation tendency.6 Poly-L-lysine modification demonstrated high cellular uptake but 
also cellular toxicity.19 The cellular toxicity may be mitigated by using lower weight 
poly-l-lysine that would reduce its’ cationic charge density. This would also reduce 
cellular uptake. Cell penetrating peptides such as TAT have exhibited increased cellular 
uptake of MSN, however this increased uptake is unspecific and would affect both 
normal and cancerous cells.  
Ligand mediated targeting is a promising solution to reducing off-target effects 
and deliver the particle to its intended target. While only one group has studied targeting 
ligands in the context of MSN for oligonucleotide delivery, many studies have employed 
this strategy for cancer therapy that are outside the scope of this review.18, 33-34 Ashley 
and colleagues demonstrated this potential with the targeting peptide SP94 that 
preferentially targeted liver cancer cells (Hep3B) while avoiding uptake by healthy 
hepatocytes.12 
Triggered release systems are another strategy purposed to limit loss of cargo 
caused by diffusion and a burst release upon entering the cancerous cell. The two main 
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strategies take advantage of the increased acidity and reducing agents in cancer cells 
because of their rapid growth. Sun and colleagues developed a redox triggered capping 
system by covering their loaded particles with PEI cross-linked with DSP.1 This system 
demonstrated redox triggered release and resulted in significantly reduced expression of 
the targeted protein in both in vitro and in vivo studies. Li and colleagues combined these 
strategies to create a pH and redox triggered system that would release the positively 
charged amine group electrostatically attaching the pDNA to the particle.30 The system 
successfully protected the loaded pDNA from degradation by DNase1 and exhibited 
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CHAPTER 4: CONCLUSION 
 
4.1 Optimizing external loading delivery systems 
Externally loaded delivery systems tend to use a small core silica nanoparticle 
and have a final diameter after exterior modifications between 20-230 nm. Unfortunately, 
few comparative conclusions concerning the optimal diameter can be reached due to the 
variety of exterior modifications between the studies (amine, PEI, PEI and PEG, etc.) 
and silica synthesis methods. Only Ngamcherdtrakul and colleagues compared different 
silica core sizes, although that group used a mesoporous silica nanoparticle core rather 
than solid silica. Future studies comparing efficacy of various diameter systems and 
previously explored external modifications such as PEI and PEG would greatly enhance 
the field.  
Systems externally loading oligonucleotides must both electrostatically hold and 
protect their cargo while also being biocompatible and targeting cell uptake. Amino 
decorated nanoparticles (NPs) are able to load and deliver DNA with similar success to 
Lipofectin when investigated in vitro in some studies,1 while other studies compared 7.5 
times as much of their amino decorated silica NP to Lipofectin.2 While tumor uptake and 
gene expression was enhanced when Tat/HA2 NP were administered intratumorally, 
intravenous injection resulted in uptake by the RES system and the majority of gene 
expression in the spleen and liver.3 A solution to avoiding immune system uptake is 
decorating the exterior with PEG. Ngamcherdtrakul’s group had greater success 
intravenously injecting their PEI and PEG decorate NP (58.6% tumor reduction)4 likely 
due to PEG’s ability to increase circulation time.  
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Although the toxicity of PEI remains a concern,5 several groups reduced PEI’s 
toxicity by conjugating it with PEG and/or using a lower weight PEI. Lee and colleagues 
found between 90-100% cell viability when incubated with 25 kDa PEI and PEG 
decorated NPs. Another group, Ngamcherdtrakul and colleagues, determined their 
nanoparticles were non-toxic when functionalized with crosslinked 1.8 or 10 kDa PEI 
and decorated with PEG.4  
While Ngamcherdtrakul’s group compared their findings to FDA approved 
Abraxane (Paclitaxel-albumin conjugates), Lee’s group did not make an outside 
comparison. This hinders cross comparison between studies and reinforces the need for 
a benchmark. For exterior loading nanoparticles, an FDA approved formulation like 
Abraxane is ideal. Abraxane has a particle size of ~130 nm6 that would likely be similar 
to a silica based formula. Furthermore, both an exterior loading silica nanoparticle 
formula and Abraxane load and deliver a hydrophobic molecule. The benchmark 
comparison would then change once a nanoparticle formula with external loading is 
approved by the FDA. 
 
4.2 Optimizing internal loading delivery systems 
Much like externally loaded systems, internal loading systems can vary in 
synthesis methods, functionalization, size, etc. Because of this, comparisons between 
studies is sometimes tenuous. However, several useful lessons can be discerned from the 
aforementioned studies. Furthermore, many studies are beginning to compare their 
systems to FDA approved liposome formulations. Liposomes are a natural benchmark, 
92 
 
since they also encapsulate their cargo, can be decorated with PEG, targeting moieties, 
and cell penetrating peptides. 
 
4.2.1. Pore size 
While there is still much work to be done in understanding the optimal pore size 
for DNA and siRNA loading and release, it is clear that larger pore sizes tend to optimize 
DNA and pDNA loading, while an intermediate pore size allow for the highest siRNA 
adsorption and release. For example, larger, amine functionalized pores (10 or 23 nm) 
adsorbed more DNA and pDNA respectively than smaller, amine functionalized pores 
(2, 3.4, and 5.4 nm).7-8 For siRNA larger pores adsorb more oligonucleotides but create 
an energetically favorable environment that hinders release. Thus, studies found 
intermediate sized pores (8 or 10 nm) were optimal compared to smaller and larger pores 
(2, 4, 7, 15, 23 nm).9-10 The ideal pore size for the MSN will change depending on 
whether a bulky functionalization is used that reduces the functional pore diameter.  
As pore size is fine-tuned, synthesis techniques for large pore MSN are also being 
perfected. The most commonly used method is expanding the synthesized pores with the 
swelling agent TMB. However, this method can result in structural instability for larger 
final pore sizes. Other avenues explored by studies loading and delivering 
oligonucleotides include additional silica precursors (BTES)11 and microemulsion 
templating.12 Compared to base prepared mesoporous silica, microemulsion templating 
results in a wider variation in particle diameter (100 – 200 nm and ~100 – 400 nm after 
size exclusion respectively). This wide range may hinder in vivo development depending 
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on whether the size range results in different delivery outcomes. The addition of BTES 
in the sol-gel method results in smaller, monodisperse MSN (50.75 nm). 
 
4.2.2. External functionalizations for delivery 
The most common base functionalization is PEI, while the second common is a 
combination of PEI and PEG. This is likely due to PEI’s ability to be endocytosed by 
cells, escape the endosome, and enter the cell’s nucleus even when unconjugated.13 
Furthermore, shorter chain PEI (<10 KDa) have been demonstrated as not causing 
significant toxicity in normal and tumor cells.14-15 PEG is usually added to reduce protein 
adsorption in vivo and reduce aggregation.16  
Upon this PEI and/or PEG base, a variety of peptides or antibodies can be 
attached. Cell penetrating peptides can increase cell uptake and direct intercellular fate 
(such as Tat).11 This can be combined with a targeting ligand to specify delivery to a 
certain cancer cell type. Both cell fusion peptides and targeting moieties have 
demonstrated efficacy when studied in vitro. Clearly the next step is to evaluate in vivo 
effectiveness. Since both targeting and cell uptake ligands require proximity to function, 
other methods to ensure this proximity is achieved will need to be employed.  
Two techniques to increase the probability that the MSN formulation will reach 
a close enough proximity to the targeted cancer cell that are usually employed are 
increasing circulation time17 (often with PEGylation) and triggered release systems to 
ensure the payload is not diminished during circulation time. Both strategies aim to 
reduce off-target effects and delivering the maximum amount of cargo to the cancer cell’s 
cytosol. The most pursued system exploits the large difference in reducing agents in 
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tumor cells compared to normal tissue. The capped pores reduce oligonucleotide loss via 
diffusion and result in higher gene delivery. For example, Sun and colleagues reported 
in vitro treatment of KB cells by siRNA loaded MSN decorated with either just PEI 
(MSN/PEI) or crosslinked PEI (MSN/CrPEI) that released its cargo upon reducing 
conditions. When compared with the control group, the MSN/PEI downregulated the 
targeted gene 40% (P < 0.05), while MSN/CrPEI downregulated it 75% (P < 0.01).18 
Unfortunately the only group that performed in vivo testing injected the triggered release 
system peritumorally.18 Thus, more studies investigating the effectiveness of reducing 
triggered systems in vivo are needed. 
 
4.3 Final thoughts 
Silica based oligonucleotide delivery systems are a promising alternative to 
medication currently on the market due to their ability to reduce cargo leakage, off-target 
effects, and target the intended cells for treatment. While much progress has been made 
in the last ten years, many obstacles still lie ahead before a delivery system will make the 
transition from bench to bedside. One strategy that would further the field as a whole 
would be to compare solid and mesoporous silica nanoparticle formulations to an FDA 
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